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Summary 
 
The massive remodeling of the heart tissue, as observed in response to pressure 
overload or myocardial infarction, is considered to play a causative role in the 
development of heart failure. Alterations in the heart architecture clearly affect the 
mechanical properties of the heart muscle, but they are rooted in changes at the 
cellular level including modulation of gene expression. Together with integrins, the 
transmembrane receptors linking the extracellular environment to the cytoskeleton, 
extracellular matrix (ECM) proteins and matricellular proteins are key components of 
the remodeling process in the heart. Therefore, this thesis was aimed at analysing 
the role of integrins in the regulation of gene expression and heart muscle 
performance during cardiac wound repair induced by pressure overload or 
myocardial infarction (MI). 
To investigate the contribution of integrin β1, we characterised the response of 
mice with a conditional, cardiac-specific deletion of the integrin β1 gene in an 
experimental model of pressure overload by aortic banding (AB). In particular, we 
measured physiological alterations and gene expression events in the stressed heart 
in the presence or absence of integrin β1. Interestingly, mice containing a knock-out 
allele and the ventricular myocyte-specific conditional allele of the integrin β1 gene 
were born and grew up to adulthood. Though these animals still exhibited minor 
amounts of integrin β1 in the heart (expressed by non-myocytes), these mice 
displayed abnormal cardiac function and were highly sensitive to AB. Whereas a 
compensatory hypertrophic response to pressure overload was observed in wildtype 
mice, the integrin β1-deficient mice were not able to undergo heart tissue remodeling. 
Furthermore, ECM gene expression was altered and, in particular, the increased 
expression of the matricellular protein SPARC after AB was abolished in integrin β1–
deficient mice.  
Interestingly, we also found a transient upregulation of SPARC mRNA during 
heart remodeling after MI using cDNA macroarrays. Indeed, increased SPARC 
protein levels were observed starting at day 2 (2.55±0.21fold, p<0.01), day 7 
(3.72±0.28 fold, p<0.01) and 1 month (1.9±0.16 fold, p<0.01) after MI, which could be 
abolished by using an integrin αv inhibitor in vivo. Immunofluorescence analysis of 
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heart tissue demonstrated that the increased SPARC expression was confined to the 
infarcted area and occurred together with the influx of fibroblasts into the heart. 
In vitro, either TGF-β1 or PDGF-BB stimulated SPARC expression by 
fibroblasts. Inhibition of integrin αv did not interfere with TGF-β1 or PDGF induced 
SPARC secretion as determined by ELISA assays or Western blot. However, 
secretion of TGF-β1 and PDGF-BB by cardiomyocytes was induced by vitronectin, a 
ligand of integrin αv, and this response was blocked by the integrin αv inhibitor. 
Functionally, SPARC modulated the migratory response of fibroblasts towards ECM 
proteins suggesting that the local deposition of SPARC following MI contributes to 
scar formation. 
Taken together, our combined in vivo and in vitro data demonstrate that 
several integrin subunits play critical roles during tissue remodeling in the injured 
heart. Integrin-dependent gene expression events such as the upregulation of 
SPARC following MI are critical to orchestrate the healing response. These 
processes appear to involve complex cross-talk between different cell types such as 
cardiomyocytes and fibroblasts to allow for locally confined scar formation. The 
elucidation of the sophisticated interplay between integrins, matricellular proteins 
such as SPARC, and growth factors will undoubtedly provide us with a better and 
clinically useful understanding of the molecular mechanisms governing heart 
remodeling. 
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Zusammenfassung 
Der enorme Umbau des Herzgewebes, wie man ihn nach Drucküberlastung 
des Ventrikels oder MyokardInfarkt beobachten kann, gilt als eine der kausalen 
Ursachen des Herzversagens. Die Veränderungen in der Architektur des Herzens 
beeinflussen die mechanischen Eigenschaften des Herzmuskels, begründet sind sie 
jedoch in Anpassungsprozessen auf der zellulären Ebene vor allem in einer 
Modulation der Expression bestimmter Gene. Gemeinsam mit Integrinen, den 
Transmembran-Rezeptoren, welche die extrazelluläre Umgebung mit dem 
intrazellulären Zytoskelett verbinden, gehören Proteine der extrazellulären Matrix 
(ECM) und matrizelluläre Proteine zu den Schlüsselkomponenten, die den 
Umbauprozess im Herzen steuern. Aus diesen Gründen hatte diese Doktorarbeit 
zum Ziel, die Rolle der Integrine für die Regulation der Genexpression und die 
Leistungsfähigkeit des Herzmuskels während der durch Drucküberlastung oder 
myokardialen Infarkt (MI) hervorgerufenen Wundheilungsprozesse zu analysieren. 
Um die Beteiligung von Integrin β1 zu untersuchen, wurde ein experimentelles 
Modell der Drucküberlastung im Mausherzen (aortic banding; Konstriktion der Aorta; 
AB) eingesetzt, wobei Mäuse mit einer konditionalen, Herz-spezifischen Deletion des 
Integrin β1 Gens untersucht wurden. Ein besonderes Augenmerk wurde dabei auf 
die physiologischen Unterschiede und eine veränderte Genexpression im 
gestressten Herzen in An- oder Abwesenheit von Integrin β1 gelegt. 
Interessanterweise wurden die Mäuse, welche eine Kombination aus Integrin knock-
out Allel und dem Kardiomyozyten-spezifischen konditionalen knock-out Allel von 
Integrin β1 aufwiesen im normalen Mendelschen Verhältnis geboren und wuchsen 
normal auf. Obwohl diese Tiere immer noch geringe Mengen von Integrin β1 in ihrem 
Herzen aufwiesen (exprimiert von nicht-Myozyten), besaßen diese Mäuse eine 
veränderte Herzfunktion und waren sehr sensitiv gegenüber AB. Im Gegensatz zu 
der kompensatorischen hypertrophischen Reaktion, die in Wildtyp Mäusen zu 
beobachten war, zeigte sich in den Integrin β1–defizienten Mausherzen kein 
Gewebeumbau. Auch die erhöhte Expression von verschiedenen ECM Proteinen, 
insbesondere die verstärkte Expression des matrizellulären Proteins SPARC, 
unterblieb nach AB in den Integrin β1–defizienten Tieren. 
Interessanterweise konnte auch eine transiente Erhöhung der SPARC mRNA 
während der Umbauprozesse im Herzen in Folge von myokardialem Infarkt (MI) 
mittels cDNA Makroarrays festgestellt werden. In der Tat fanden sich größere 
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Mengen von SPARC bereits 2 Tage (~2,5-fach erhöht), 7 Tage (~4-fach erhöht) und 
1 Monat (~2-fach erhöht) nach MI, während ein spezifischer Inhibitor der Integrin αv 
Untereinheit diese Hochregulation von SPARC in vivo verhinderte. 
Immunfluoreszenz Untersuchungen von Herzgewebe verdeutlichten, dass sich die 
erhöhte Expression von SPARC auf das Infarktareal beschränkte, dass die 
Expression von SPARC nach einer anfänglichen Erhöhung im Verlauf von 1 Monaten 
wieder auf das Anfangsniveau zurückging und dass die verstärkte Expression von 
der Einwanderung von Fibroblasten in das ischämische Herzgewebe begleitet war. 
In vitro stimulierten die Wachstumsfaktoren TGF-β1 und PDGF-BB die 
Expression von SPARC durch Fibroblasten. Wie sich an Hand von ELISA und 
Western Blot Untersuchungen feststellen ließ, war die Inhibition von Integrin αv nicht 
in der Lage, die durch TGF-β1 oder PDGF induzierte Sekretion von SPARC zu 
beeinflussen. Jedoch zeigte sich, dass Vitronektin, ein Ligand von Integrin αv, sowohl 
die Sekretion von TGF-β1 als auch von PDGF-BB durch Kardiomyozyten induzierte 
und diese Reaktion wurde durch den Integrin αv Inhibitor komplett unterdrückt. In 
funktioneller Hinsicht wirkte SPARC auf die durch ECM Proteine induzierte Migration 
von Fibroblasten ein, so dass man davon ausgehen kann, dass die lokale 
Freisetzung von SPARC nach myokardialem Infarkt zur Wundheilung im Herzen 
beiträgt. 
Zusammenfassend läßt die Kombination der in vivo und in vitro erhobenen 
experimentellen Daten den Schluss zu, dass mehrere Integrin Untereinheiten eine 
entscheidende Rolle während der Gewebeumbildung im Herzen spielen. Integrin-
abhängige Genexpressionsereignisse wie beispielsweise die erhöhte Expression von 
SPARC nach MI sind entscheidend an der Koordination der Wundheilung beteiligt. 
Diese Prozesse scheinen auf einer komplexen Wechselwirkung und Kommunikation 
zwischen verschiedenen Zelltypen wie Kardiomyozyten und Fibroblasten zu beruhen, 
um lokal begrenzt eine Heilung und Vernarbung des verletzten Gewebes zu 
regulieren. Die Aufklärung des fein abgestimmten Wechselspiels zwischen Integrinen 
matrizellulären Proteinen wie SPARC und Wachstumsfaktoren wird sicherlich zu 
einem besseren und klinisch nutzbarem Verständnis der molekularen Mechanismen 
des Gewebeumbaus im Herzen beitragen.  
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1. GENERAL INTRODUCTION 
 
When the heart has to work too hard to maintain adequate blood output, it can 
begin to change shape, with the left ventricle often growing larger, less flexible and 
weaker. Prolonged compensation for these impairments can change both the heart 
structure and its function. This combination is known as remodeling of the heart 
  
       
1.1. Myocardial infarction and cardiac hypertrophy  
 
Cardiovascular diseases, in particular hypertrophic and ischemic heart disease, are 
leading cause of death in industrialized countries. Remodeling of the myocardium is 
the major mechanism underlying disability and death in recent cardiovascular 
diseases (Ertl, Gaudron et al. 1993) 
 
1.1.1. Acute events upon acute myocardial infarction 
 
When a coronary artery becomes totally blocked, the inadequate arterial oxygen 
supply to the myocardium produces an acute myocardial infarction (MI). As a result 
of acute ischemia after MI, excitation–contraction uncoupling occurs determining 
cardiac systolic and diastolic dysfunction. Myocardial ischemia has been viewed for 
many decades as an all-or-none process that causes myocardial necrosis when 
prolonged and severe, but the effects are transient when it is brief, mild or prompt 
reperfusion occurs (Braunwald and Kloner 1982; Cohn 1993). Persistence of 
ischemia leads to irreversible cell death. Ischemic necrosis is diagnostic 
pathognonomic of acute myocardial infarction. Apoptosis may represent an important 
pathophysiological mechanism causing progressive cardiomyocyte loss and left 
ventricular dilation after acute myocadial infarction. (Abbate, Biondi-Zoccai et al. 2002) 
Adaptative processes after myocardial ischemia play an important role in the 
progression of left ventricular remodeling. Either occlusion of a coronary artery or 
chronic severe coronary artery stenosis leads to myocardial cell loss with consecutive 
necrosis and scar formation. Following myocardial ischemia reactive neovascularization 
(angiogenesis) occurs in the myocardial regions bordering and remote from the scar. 
Ischemic necrosis is diagnostic pathognonomic of acute myocardial infarction 
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Apoptosis may represent an important pathophysiological mechanism causing 
progressive cardiomyocyte loss and left ventricular dilation after acute myocardial 
infarction (AMI).(Abbate, Biondi-Zoccai et al. 2002). Apoptosis represents the major 
form of death, being several times more common than necrosis. Myocardial 
apoptosis peaks at 4-12 h in AMI and is persistently demonstrable up to 10 days 
(Cohn 1993; Cheng, Kajstura et al. 1996) (Olivetti, Abbi et al. 1997). Necrosis of 
cardiomyocyte is usually completed within 24-48 h following coronary occlusion, 
phagocytosis and removal of cellular debris by inflammatory cells starts at 24 h 
(Lodge-Patch 1951; Fishbein, Maclean et al. 1978). A reduction in myocardial 
apoptosis have already been shown to contribute to improve the prognosis and 
symptoms in patients with post-infarction heart failure.(Holtz 1998).  Characteristically, 
features of acute inflammation are observed within the first 24-72 h and are 
associated with further reduced cardiac performance, while macrophages infiltrate 
the infarcted myocardium days later. Myocardial infarction involves scar-formation 
mechanisms in which inflammation, proliferation, cell differentiation, apoptosis and 
angiogenesis all play a role. After an inflammatory phase in which polymorphon 
nuclear neutrophils colonized the scar, granulation tissue set in with a proliferation of 
myofibroblasts and growth of new blood vessels. These cells disappeare from the 
scar gradually, leaving behind a matrix rich in collagen and devoid of any contractile 
properties. 
 
1.1.2. Left ventricular remodeling and hypertrophy in myocardial infarction  
 
Two myocardial processes are initiated by acute myocardial infarction: hypertrophy of 
the residual myocardium and a change in left ventricular chamber dimension. In 
response to a transmural myocardial infarction (MI), the left ventricle (LV) undergoes 
significant remodeling (Pfeffer and Braunwald 1990). The sequence of these events 
appears to be critically dependent on the size of the infarct and its distensibility, on 
the load placed on the myocardium, on the metabolic state of adjacent and remote 
myocardium, and on the degree of activation of tissue hormone systems. 
Hypertrophy may occur transversely (concentric) or longitudinally (eccentric). 
Myocardial injury following MI induce LV remodeling events that continue for months 
and even years. The chamber may enlarge because of cell lengthening or slippage 
or because of infarct expansion. In vivo, left ventricular remodeling after myocardial 
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infarction involves hypertrophy generally attributed to increased cardiac workload. 
Transient hypoxia may contribute to cardiac hypertrophy in ischemic heart disease 
independent of cardiac workload. Furthermore, increase for the surviving 
myocardium may activate signalling cascades that induce cardiac hypertrophy, 
functional deterioration and failure. Hypertrophy is an adaptive response to 
compensate for impaired cardiac function. (El Jamali, Freund et al. 2004). 
Remodeling is a repair process. It can follow myocardial infarction, mechanical 
overload (for example, in hypertension or valvular heart disease), and also occurs in 
inflammation and dilated cardiomyopathy. Remodeling can be an (early) adaptive 
process followed by a maladaptive (late) phase and involves all cells that are present 
in the myocardium - the myocyte, the interstitial cells, the vascular endothelium, and 
the immune cells. Despite the varying etiology that these different aspects of heart 
disease share, a similar sequence of molecular, biochemical and mechanical events 
that can lead to heart failure, myocyte hypertrophy, extensive extracellular matrix 
production and fibrosis. The rearrangement of the components of the ventricular wall 
and subsequent development of chronic heart failure after ischemic myocardial injury 
plays an important role in the development of cardiac failure after myocardial 
infarction. Although left ventricular remodeling appears to represent an adaptive 
process serving to preserve stroke volume (and cardiac output) following myocardial 
injury, the enlargement process may have undesirable long-term effects on global left 
ventricular function and on clinical prognosis. Recent observations suggested that 
this long process has a deleterious effect on LV function and prognosis. (Abbate, 
Biondi-Zoccai et al. 2002). Fortunately, recent experimental and clinical evidence 
demonstrates that ventricular remodeling and its deleterious consequences may be 
preventable.  
 
1.1.3. Alterations in cardiac gene expression after myocardial infarction and  
hypertrophy  
 
Recent technological advances in the production of cDNA microarrays have made it 
possible to profile gene expression of tens of thousands of genes simultaneously 
(Brown and Botstein 1999). More than 200 genes were identified that showed 
differential expression in response to myocardial infarction. (Stanton, Garrard et al. 
2000).  It is clear that substantial alterations in gene expression are needed to afford 
such profound changes within cells of the remodeling myocardium. Alterations in 
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expression of several genes have been described in the experimental model of MI in 
rat. Changes in actin and myosin gene expression are associated with alterations in 
cytoskeleton and contractile apparatus in surviving cardiomyocytes (Meggs, Tillotson 
et al. 1990).  Fibrosis of LV myocardium is, in part, the result of elevated collagen and 
fibronectin expression. (Murakami, Kusachi et al. 1998). Atrial natriuretic peptide 
mRNA and protein levels in the cardiomyocyte are increased in response to MI as a 
compensatory response to improve hemodynamics (Mendez, Pfeffer et al. 1987). In 
addition, certain cytokine genes, transforming growth factor beta 1 (TGF-beta(1)) 
interleukins 1ß and 6, and tumor necrosis factor-  are transcriptionally regulated in 
the remodeling MI rat heart. (Dai, Dheen et al. 2002). 
 Cardiac hypertrophy is accompanied by distinct qualitative and quantitative 
changes in gene expression. Specific changes have been observed in 
cardiomyocytes during the development of cardiac hypertrophy (Cooper 1987; 
Ruwhof and van der Laarse 2000) e.g. quantitative and qualitative changes in gene 
expression, rapid induction of proto-oncogenes (such as c-fos. C-jun, and c-myc) and 
heat shock protein genes (such as hsp 70). which are the first response 
hemodynamic overload (Izumo, Nadal-Ginard et al. 1988). As a later event, the 
expression of several genes that encode sarcomeric proteins is switched to 
expression of fetal isoforms, for example transition from cardiac α-actin to skeletal α 
actin. Hypertrophy is characterized by an increase in cell size in the absence of cell 
division, actin, and from the α-form of myosin heavy chain (MHC) to the β-MHC form 
in rodents (Schwartz, de la Bastie et al. 1986). In addition, several changes in 
isogene expression of proteins involved in energy metabolism have been described 
(Revis, Thomson et al. 1977; Meerson and Javich 1982). Furthermore, the 
expression of atrial natriuretic peptide (ANP) that is restricted to the atria shortly after 
birth, is reappearing in the ventricles upon hemodynamic overload (Mercadier, 
Samuel et al. 1989). Besides the qualitative changes in gene expression described 
above, there are also quantitative changes in constitutive expression of genes, i.e. 
stimulation of gene expression which contributes to hypertrophy, and down-
regulation of genes. Several genes that encode membrane proteins are down-
regulated in hypertrophied hearts, for example, the sarcoplasmic reticulum Ca2+-
ATPase (SERCA) gene(Anger, Lompre et al. 1998). The rate of protein synthesis is 
probably increased by a different mechanism although its involvement in the 
development of cardiac hypertrophy has to be proven.  
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1.2. Mechanisms and signal transduction pathways of cardiac 
hypertrophy  
 
Pressure overload of the heart leads to an increase in wall stress. This frequently 
results in cardiac hypertrophy, which is induced by the mechanical stress on the 
cardiomyocytes and the activation of neuroendocrine mechanisms, particularly the 
renin-angiotensin-aldosterone system and the sympathetic nervous system. 
Myocardial hypertrophy represents an independent risk factor for cardiovascular 
events such as ischemic heart disease, arrhythmias, and sudden death and is a 
powerful predictor for the development of heart failure. (Levy, Garrison et al. 1990). 
Development of cardiac hypertrophy is initially beneficial since it augments the 
number of contractile units and reduces ventricular wall stress to normal levels 
according to the law of Laplace. However, the adaptation has its limits and heart 
failure may ensue. Furthermore, arrhythmias and ischemic heart disease may 
develop, which increase the risk of sudden death. 
 
1.2.1.Stimuli inducing cardiac hypertrophy  
 
1.2.1.1. Mechanical stress  
Mechanical stress is considered to be the trigger inducing a growth response in the 
overloaded myocardium. Cardiac hypertrophy can be induced by hemodynamic 
overload even after adrenoreceptor blockade (humoral) or sympathectomy 
(neural)(Cooper, Kent et al. 1985). This suggested that mechanical stress itself is the 
primary factor for cardiac hypertrophy in response to hemodynamic overload. The 
view was supported by several ex vivo and vitro studies. Kiral et al demonstrated that 
in isolated hearts, an increased cardiac load stimulated protein synthesis (Kira, 
Kochel et al. 1984). Further more, alterations in gene expression in stretching 
cultured cardiomyocytes were observed without involvement of neural or humoral 
factors (Komuro, Kaida et al. 1990; Sadoshima, Jahn et al. 1992; Kira, Nakaoka et al. 
1994; Vandenburgh, Solerssi et al. 1995). Moreover, the alternations in vitro 
experiments using stretched cardiomyocytes have been demonstrated to be similar 
to those in vivo hearts in response to hemodynamic overload, i.e. re-expression of 
fetal genes and increased protein synthesis do also occur in isolated cells in vitro. 
These findings demonstrated that mechanical stress is possibly the main contributor 
to the hypertrophy. 
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1.2.1.2. Growth factors and hormones  
Besides mechanical loading, a range of substances, such as growth factors, 
cytokines, catecholamines, vasoactive peptides and hormones are involved in 
mediating cardiac myocyte hypertrophy(Hefti, Harder et al. 1997).(Sacca, Napoli et 
al. 2003)  The expression and /or release of these factors have been reported in 
hearts that hypertrophied due to hemodynamic overload, and in cardiomyocytes that 
are hypertrophied due to stretch. The classic peptide growth factors can be divided 
into five families: epidermal growth factor (EGFs,) Fibroblast growth factor (FGFs), 
Insulin-like growth fachor (IGF), platelet derived growth factor (PDGFs) and 
transforming growth factor (TGFs). TGFβ and PDGF have been shown to cause 
cardiomyocyte hypertrophy in vitro systems. In the heart, PDGF is produced by non-
myocytes. FGF and TGFβ can be produced by cardiac myocytes and non-
myocytes(Brand and Schneider 1995; Seger and Krebs 1995), therefore, these two 
factors may act in a paracrine or autocrine manner in the heart. Smad proteins have 
been identified as the first family of putative TGF-β signal transducers (Kretzschmar, 
Liu et al. 1997) Upon phosphorylation by actived receptors, Smad associate with 
DNA binding proteins and activate gene transcription. Thus, cardiac myocytes and 
other cell types, such as cardiac fibroblasts, endothelial cells and vascular smooth 
muscle cells, may secrete growth promoting factors after a mechanical stress 
stimulus, which induce hypertrophy of cardiomyocytes in an autocrine/paracrine way. 
 
1.2.2. SIGNAL TRANSDUCTION OF THE STRETCH STIMULUS 
 
The signal transduction pathways that may be involved in mechanical stress-induced 
hypertrophy belong to two groups: (1) the mitogen-activated protein kinases (MAPK) 
pathway; and (2) the janus kinase/signal transducers and activators of transcription 
(JAK/STAT) pathway. The MAPK pathway can be subdivided into the extracellular-
regulated kinase (ERK), the c-Jun N-terminal kinase (JNK), and the 38-kDa MAPK 
(p38 MAPK) pathway. Nowadays,it is known that there are several interactions 
between these pathways. In fact, mechanical stress appears to activate both 
pathways. 
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Figure 1.1 Schematic diagram of the signal transduction cascades that are involved 
in stress-induced cardiac hypertrophy. More informations are described in the text.  
 
1.2.2.1 The mitogen-activated protein kinase (MAPK) pathway 
1) The extracellular-regulated kinase (ERK) pathway. 
The best characterized are: the 44-kDa MAPK (ERK1), the 42-kDa MAPK (ERK2), 
and the 63-kDa MAPK (ERK3). In the heart, ERK1 is the most highly expressed 
ERK. The expression of ERK3 is hardly detectable in adult heart. Substrates for 
ERKs are transcription factors, such as c-jun, and p62TCF (Elk-1), and the 90-kDa S6 
kinase (p90RSK)(Boulton, Nye et al. 1991). Mechanical stress has  been reported to 
stimulate this pathway by  activation of Ras, ERK1 and ERK2, and p90RSK 
(Sadoshima and Izumo 1993).The precise mechanism of the stimulation of this 
pathway is still unknown. Moreover, stretch of cardiomyocytes caused activation of 
ERKs and resulted in increased expression of c-fos and skeletal α-actin, indicating 
that ERKs and mechanical stress-induced hypertrophy may be linked (Sadoshima 
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and Izumo 1993) Taken together, these results indicate that the ERKs may partly 
participate in the mechanisms of mechanical stress-induced hypertrophy. 
 
2) The c Jun N-terminal protein kinase (JNK) pathway 
The JNK pathway may be involved in mechanical stress-induced hypertrophy via 
phosphorylation of the transcription factors c-Jun, and ATF2 (Clerk and Sugden 
1997). This activation of JNKs was independent of secreted Ang II, extracellular Ca2+, 
and PKC. Others have found that cardiomyocytes submitted to cyclic stretch had a 
maximal activation of JNKs at about 5 min. Using MEKK1-transfected 
cardiomyocytes, Thorburn et al. (Thorburn, Xu et al. 1997). showed that 
overexpression of MEKK1 induced ANP expression (a marker of hypertrophy). 
Furthermore, these authors found that the small G protein Rho was also required for 
MEKK1-induced ANP expression (Thorburn, Xu et al. 1997). Controversially, Nemoto 
et al. found that activation of JNKs inhibited MEKK 1-induced ANP expression via a 
feedback loop of c-jun. They reported that ANP expression is activated by p38 
MAPKs. Taken together, it seems that the induction of ANP expression is biphasic, 
first a short-living response upon JNK activation followed by a prolonged response 
upon p38 MAPK activation. 
 
3) The p38 MAPK pathway 
The function of the p38 pathway in myocardial hypertrophy has recently been 
studied. It has been observed that p38 and p38β activity were increased in a mouse 
model of pressure overloading and that the p38 and p38 β activity were well 
correlated with phenotypic ventricular hypertrophy (Wang, Harkins et al. 1997) In 
these experiments, introducing constitutively active MKK6 or MKK3 into cardiac 
myocytes elicited characteristic hypertrophic responses, including an increase in cell 
size, enhanced sarcomeric organization, and elevated atrial natriuretic factor 
expression. The two isoforms of p38 group kinase, p38 and p38β, appear to have 
different effects on cardiomyocyte hypertrophy: p38β seems to be more potent in 
inducing hypertrophy, whereas p38 appears to be more important in other function 
such as apoptosis. Interestingly, the hypertrophic response induced by p38 MAPKβ 
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included several markers of hypertrophy, i.e. an increase in cell surface area, 
enhanced organization of sarcomeric proteins, and induction of ANP expression 
(Wang, Huang et al. 1998). 
 
1.2.2.2. The janus kinase/signal transducers and activators of transcription  
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) 
pathway 
Janus –associated kinases are named after their dual functions in signal trsduction in 
the cytoplasm and activation of transcription in the nucleus. Binding of ligands to their 
cytokine rceptors, such as dardiotriphin-1 (CT-1), leads to phosphorylation and 
activation of the receptor-JAK complex with subsequent recruitment of STATs and 
activation of STATs by phosphorylation. The JAK/ STAT pathway was found to be 
activated in rat hearts with pressure overload-induced hypertrophy (Pan, Fukuda et 
al. 1997). The JAK/ STAT pathway was found to be activated in rat hearts with 
pressure overload-induced hypertrophy of Mechanical stretch induced rapid 
phosphorylation of JAK1, JAK2, Tyk2, STAT1, STAT3, and glycoprotein 130  was  
observed as early as 2 minutes and peaked at 5 to 15 minutes. (Tian, Cui et al. 
2004). Moreover, studies clamed that the mechanical stress-induced activation may 
occur via gp130. 
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1.3. Extracellular matrix and cardiac remodelling. 
Significant remodeling of the extracellular matrix (ECM) occurs in cardiac 
hypertrophy and in the acute (healing) and chronic (remodelling) stage after 
myocardial infarction Today we know that the extracellular matrix (ECM) is important 
because it not only support cardiac structure but also because the ECM is essential 
in cardiac function and responses to pathophysiological signals. Its modifications are 
associated with cardiac hypertrophy and heart failure, and the molecular basis 
bringing a better insight into the dynamics of the ECM. The ECM is a key component 
in the remodeling process, and increases in collagen occur in the infarct area to 
replace necrotic myocytes and to form a scar. There was marked up-regulation of 
mRNAs for extracellular matrix (ECM) proteins and their cross-linking enzyme, such 
as collagens type I, III and VI, and lysyl oxidase in the injured heart. Over the last 
several years, it has become increasingly evident that disruption of extracellular 
matrix (ECM) homeostasis is a deciding factor for the progression of myocardial 
failure. 
 
1.3.1 Extracellular matrix in myocardium  
Although the myocytes subserve the heart's pump function, the predominant cell type 
by numbers in the heart is the fibroblast (not the myocyte). About two thirds of 
myocardial cells are fibroblasts. Cardiac fibroblasts (CF) grow in a complex tissue 
environment and are responsible for the production and deposition of the majority of 
ECM proteins in the cardiac interstitium. Several matrix proteins are expressed in the 
normal myocardium, including Collagens, laminin, fibronectin, and chondroitin 
sulphate. Collagen is the most abundant protein in the body, and collagen 1 
represents about 90% of total collagen. Collagen I, collagen III, and collagen IV are 
the predominant collagens in the myocardium. As a whole, the ECM provides an 
environment for cells to migrate, grow, and differentiate, establishing a connection 
between cell and tissue function. The ECM is coupled to the cell through cell surface 
receptors, the most important ones are the integrins. 
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1.3.2. Collagen in the heart  
Collagens, the chief components of extracellular matrix, are a tightly regulated family 
of proteins that determine the structural and functional integrity of heart. Collagen 
type I and type III comprise approximately 85% and 11% respectively of the cardiac 
interstitium (Weber 1989) The fibrillar collagens of the heart surround and 
interconnect myocytes and muscle fibers to provide for muscle fiber and myocyte 
alignment which imparts mechanical support to the myocardium and governs tissue 
stiffness. Excessive collagen deposition or pathological fibrosis is an important 
contributor to left ventricular (LV) dysfunction and poor outcome in hypertension, MI 
and heart failure. It is also an important problem in the aging heart. Antifibrotic agents 
that target steps in the collagen synthesis and degradation pathways therefore 
represent promising strategies for these diseases. Because reparative fibrosis is an 
essential component of healing of the infarct zone (IZ) after MI, loss of collagen fibrils 
and struts lead to myocyte slippage, ventricular dilation, and progressive contractile 
dysfunction. (D'Armiento 2002). Failed human hearts examined either at autopsy or 
explantation invariably exhibit alterations of the ECM primarily due to changes in 
collagen. Synthesis of collagens is regulated at the cellular level while deposition of 
proteins depend on a balance between matrix metalloproteinases (MMPs) and tissue 
inhibitors of matrix metalloproteinase (TIMPs).The ability of the heart to respond to 
mechanical and chemical stimuli by modulating the delicate balance between 
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synthesis and degradation of structural components of ECM has a significant impact 
on cardiac function. 
 
1.3.3. Matrix Metalloproteinases (MMP) and myocardial matrix remodelling  
 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes 
comprised of more than 25 individual members divided into specific classes based on 
in vitro substrate specificity for various ECM components. MMP family is involved in a 
wide variety biologic processes including normal embryonic development and wound 
heading, as well as pathologic processes such as tumor invasion, arthritis, 
emphysema (Matrisian 1990). Lemaitre et al demonstrated that MMP does not 
always translate into tissue destruction and emphasizes the fact that MMPs are 
critical in the remodelling of tissues in response to injury. matrix metalloproteinases 
(MMPs) play an important role in atherosclerosis by degrading the extracellular 
matrix, which results in cardiovascular remodeling. Collagen degradation is an 
important step in remodelling of the collagen matrix. Collagens are degraded 
extracellularly by members of the of MMP family 
MMPs are present in the heart and determine the interstitial architecture. 
Importantly, the activation of MMPs and their endogenous inhibitors (TIMPs) are 
associated with ventricular remodelling. Pro-fibrotic factors such as norepinephrine, 
angiotensin II  and endothelin-1 stimulate fibrosis by modulating collagen synthesis 
and MMP/TIMP activity. Congestive heart failure and changes in MMP levels have 
been described in variety of animal models of heart failure.(Pauschinger, 
Chandrasekharan et al. 2004).  During myocardial infarction, loss of collagen begins 
within minutes of the onset of ischemia, and within the first hour a marked 
deterioration in the structure and an actual decrease in the quantity of collagen has 
already occurred. This rapid initial loss of collagen is associated with enhanced 
activity of MMPs (Matrisian 1990). The initial degradation of collagen is followed by a 
rapid and progressive increase in gene expression. The generation of a transgenic 
mouse with constitutive expression of MMP-1 in the heart has suggested that this is 
an animal model of hypertrophy at 6 months of age,(Kim, Dalal et al. 2000).  This 
transgenic model provides direct evidence that disruption of the equilibrium of ECM 
synthesis and degradation can play a critical role in the process of cardiac 
remodelling and the pathophysiology of heart failure    
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1.4 The extracellular connections: the role of integrins in 
myocardial remodeling. 
 
Integrins are a large family of heterodimeric cell surface receptors that link the 
extracelluar matrix and intracellular cytoskeleton and are multifunctional, playing 
roles in cell organization and differentiation, migration, alteration of gene expression, 
and cell survival. The function as mechanotransducers has been considered the 
most interestingly from the cardiovascular viewpoint.  
 
1.4.1. Integrin structure and basic signal machinery  
 
Integrins were so named because they are both integral membrane proteins and also 
involved in cellular and ECM integrity. Integrins are the transmembrane receptor 
composed of noncovalently associated α and β subunits, with alpha subunits ranging 
in size from 120 to 180 kDa whereas β subunits are 90 to 110 kDa.(Ross 2002).  The 
ingegrin family comprises more than 18α and 24 β subunits in mammals. More than 
24 paired of integrins have been identified. The subunits of α and β integrin are signal 
transmembrane spanning proteins with the bulk of the molecule in the extracellular 
domain and generally short cytoplasmic domains. After ligand binding the integrin 
conformation is altered and subsequently the heterodimer can participate in events 
critical for organization of the cytoskeleton and other intercellular signalling events 
that might be important for cell survival or initiation of cardiac myocyte hypertrophic 
events. A major role of integrins in the heart is their ability to serve as a mechano-
transduction device during normal development and in response to physiological and 
pathophysiologic signals. Integrins can signal through the membrane in either 
direction: The extracellular activity of integrins is regulated from the inside of the cell 
(inside-out signalling), while integrin banding to the ECM elicits signals that are 
transmitted into the cell (out side-in signalling). Integrins bind to specific ECM 
proteins via their large extracellular domains and the short cytoplasmic domains of 
integrins serve as docking sites for signalling molecules, including nonreceptor 
tyrosine kinases (such as FAK), adapter proteins ( such as Grb-2 and p130Cas) and 
structural proteins (such as paxillin or talin). In addition, integrin associated 
molecules can connect integrins with cytoplasmic signalling enzymes as well as 
transmembrane growth factor receptors. Upon binding to the ECM, integrin cluster in 
the plane of the cell membrane and initiate an intracellular protein complex that 
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promotes the assembly of actin filaments. The reorganization of actin filaments into 
larger stress fibers, in turn, introduces more integrin clustering, hence enhancing the 
matrix binding and organization by integrins in a positive feedback system. Well 
developed aggregates have been detected by immunofluorescence microscopy and 
are known as focal adhesions and ECM contacts. (Giancotti and Ruoslahti 1999) 
 
1.4.2. Integrin expression in basal and pathologic myocardium  
 
The relative number of specific α and β integrin subunit expressed in the myocardium 
is small. In particular, α1, α2, α5, α7, α10 and α11 are detected in 
cardiomyocytes .(Ross 2002). These alpha integrin subunits appear to be only 
associated with splice-variants of β1 integrin, including the splice variant β1D, which 
is dominantly expressed in striated muscle and is the prime β1 integrin isoform 
expressed in postnatal heart. . Adult rat cardiac failure (CF) express a wide range of 
integrins including α1β1(most predominant) α2β1, α5β1, αvβ3, αvβ1 and α4β1,  αvβ5, 
αvβ6(MacKenna, Dolfi et al. 1998) In the adult heart, integrins are the principal 
receptors for ECM, thus their appropriate expression and function is necessary for 
the normal cardiovascular function. (Keller, Shai et al. 2001). Disruption of integrin 
function in the murine myocardium leads to perinatal lethality, fibrosis, and abnormal 
cardiac performance.(Keller, Shai et al. 2001). In vitro studies have shown that 
disruption of α1β1 function by antibodies or adenovirus  mediated inhibition resulted 
in altered phenotype of cultured myocytes and altered patterning of their myofibrils 
(Simpson, Terracio et al. 1994). 
Integrins belong to the important factors, which are responsible for the process 
or cardiac hypertrophy. Studies in vitro have directly linked β1 integrin (both isoforms 
A and D) to the hypertrophic response of neonatal ventricular myocytes. The 
hypertrophy response caused by α1 adrenergic agents was induced by the 
overexpression of these integrins.(Pham, Harpf et al. 2000). Over expression of β1 
integrin in the cardiomyocyte was found to increase protein synthesis and ANP 
expression without affection DNA synthesis. In contrast, inhibition of β1 function and 
signalling reduced the adrenergically mediated hypertrophy.(Ross, Pham et al. 1998; 
Pham, Harpf et al. 2000). Studies of integrins function in vivo have begun to be 
assessed in the myocardium of both rats and mice provoked to undergo morphologic 
hypertrophy or myocardial infarction have demonstrated the important of integrins. In 
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these rodent models, increased expression of β1A and β1D, α3, α7B were detected.  
α1and α5 integrin subunits behave like many embryonic genes in the ventricle. They 
are expressed in the embryonic heart, become down-regulated postnatally, and can 
be re-induced after mechanical loading of the heart through aortic constriction. 
Pressure overload of the right ventricle in a cat model has demonstrated the 
mobilization of β3 integrin to the cytoskeletal fraction of lysed myocardial tissue 4 
hours after banding. Integrin β3 is present in both the cytosleletal and membrane 
bound fractions by 48 hours after pressure overload. However, the levels returned to 
baseline by one week. (Kuppuswamy, Kerr et al. 1997).  
 
1.4.3. integrin signalling in the myocardium  
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Figure.1.3 Integrin signal in myocardium. Integrin are a large family of heterodimeric 
cell surface transmembrane receptors composed of noncovalently associated α and β 
subunits. Integrins link to ECM most through RGD motif binding site. The site’s 
conformation appears to determine which integrin a RGD tripeptide will bind. They 
clustered in the plane of the cell membrane and connected with a cytoskeleton and 
signalling complex that promotes the assembly of actin filaments. The reorganization of 
actin filaments into larger stress fibers, in turn introduce more integrin clustering, hence 
enhancing the matrix binding and organization by integrins in a positive feedback system. 
 
The role of integrin signalling in myocardium is still incompletely understood. Integrins 
may be implicated in cardiac hypertrophy as mechanosensors that sense increased 
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work load of the heart muscle. In an integrin (β1)-dependent and matrix-specific way, 
integrins have been shown as mechanotransducers in cardiac cells. The integrin-
dependent pathways involving FAK and Src-family kinases have been studied in some 
detail. There are two views on the mechanism of integrin mediated signalling, which 
may be complementary.  
  Some studies support the first view that integrins transmit signals by 
organizing the cytoskeleton (action filaments) through intermediary molecules 
including α-actinin, talin, vinculin, paxillin, and tensin, thereby stabilizing cell adhesion 
and regulation cell shape, morphology, and motility. (Ingber 1991; Zhang, Weinheimer et 
al. 2003). A large body of evidence suggests that mechanical stress is first received 
by integrins, and that next interlinked actin microfilaments transduce mechanical 
stress in concert with microtubules and intermediate filaments. Moreover, Bloom 
(Bloom, Lockard et al. 1996) suggested that this mechanism even could modulate gene 
expression. They showed that intermediate filaments transmit mechanical stress to 
the chromatin and hypothesized that alterations in the chromatin induce modulation 
of gene expression(Bloom, Lockard et al. 1996) 
The second view is that integrins are regarded as true receptors capable of 
inducing biochemical signals within the cell that regulate gene expression and 
cellular growth, which based on the  discovered co-localization of signaling molecules 
in focal adhesion complexes (FACs). Upon clustering of integrins at focal adhesion 
sites they recruit the non-receptor kinases FAK and Src seems to e an early event. 
This recruitment is followed by the association and activation of additional 
cytoskeletal proteins as well as signal-transducing molecules (such as Grb2, Sos, 
Ras, Raf, PLC , ERKs, and SAPKs) in the forming FACs (Miyamoto, Teramoto et al. 
1995) In these FACs signaling proteins and their substrates are brought into close 
proximity, thereby facilitating signal transduction. In fact, integrins may induce 
activation of FAK with the help of Src (Parsons and Parsons 1997), which may lead 
to activation of the ERK pathway through Grb2-Sos-Ras or through activation of 
PLC  . Integrins can also collaborate with growth factor receptors and their 
substrates to phosphorylate their receptor kinases and to activate ERKs and JNKs 
upon ligand binding (Parsons and Parsons 1997)Thus, integrins may integrate a 
variety of different signaling pathways that are activated by both the ECM and growth 
factors to establish a well-coordinated response. 
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1.5 Characterization of SPARC, one of the extracellular proteins  
 
Matricellular proteins form a group of extracellular matrix (ECM) proteins that do not 
subserve a primary structural role, but rather function as modulators of cell-matrix 
interactions. Members of the group, including thrombospondin (TSP)-1,TSP-2, 
SPARC, tenascin (TN)-C, and osteopontin (OPN), have been shown to participate in 
a number of processes related to tissue repair.(Kyriakides and Bornstein 2003) 
SPARC (Secreted Protein Acidic and Rich in Cysteine, also known as osteonectin or 
BM-40), is a 32-kDa multifunctional glycoprotein that belongs to the matricellular 
group of proteins. It modulates cellular interaction with the extracellular matrix (ECM) 
by its binding to structural matrix proteins, such as collagen and vitronectin, and by 
its abrogation of focal adhesions, contributing to a counteradhesive effect on cells. It 
is expressed spatially and temporally during embryogenesis, tissue remodeling and 
repair. SPARC functions to regulate cell–matrix interactions and thereby influences 
many important physiological and pathological processes. 
 
1.5.1. Structure and properties of SPARC 
 
SPARC is a 32 –kD protein, but the secreted form migrates at 43 kD on SDS-PAGE, 
in part due to the addition of carbohydrate.(Sage, Johnson et al. 1984)The vertebrate 
SPARC gene encodes proteins of 298–304 amino acids (aa), including three distinct 
modules, as shown in Fig 1.4. Module I [aa 3–51, previously termed domain I (Lane 
and Sage 1994) is encoded by exons 3 and 4, is highly acidic, and binds 5–8 Ca2+ 
ions with a Kd of 10−3–10−5 M. The structure of this module has not yet been solved. 
This NH2-terminal domain contains immunodominant epitope(s) and binds to 
hydroxyapatite. It is the major immunological epitope of SPARC and is also the 
region that is the most distinct from other members of the SPARC gene family. 
Therefore, antibodies against SPARC have not been found to cross react with or 
recognize SPARC-like protein.(Yan, Sage et al. 1998) 
 Module II (aa 52–132) is encoded by exons 5 and 6 and contains 10 Cys and 
an N-linked complex carbohydrate. The sequence encodes a structure that is 
homologous to a repeated domain in follistatin, a protein that binds to activin and 
inhibin, members of the TGF-β superfamily, and agrin, which induces aggregation of 
nicotinic acetylcholine receptors. Module II also contains bioactive peptides that exert 
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different effects on endothelial cells. Peptide 2.1 (aa 55–74), part of the EGF-like β 
hairpin, inhibited the proliferation of endothelial cells (Funk and Sage 1993)and 
peptide 2.3 (aa 113–130), containing the Cu2+ binding sequence GHK and part of the 
Kazal protease inhibitor-like region, stimulated endothelial cell proliferation and 
angiogenesis (Funk and Sage 1993) 
 Module III (aa 133–285, exons 7–9), formerly designated as the EC module 
also contains a sequence designated peptide 4.2 (aa 254–273), which has been 
shown to bind to endothelial cells and to inhibit their proliferation(Kupprion, Motamed 
et al. 1998). The fibril-forming collagen types I, III, and V, and the basement 
membrane collagen type IV, bind to the EC module of SPARC in a Ca2+-dependent 
fashion constitutes the extracellular Ca2+-binding (EC) module. 
 
 
 
 
Fig 1.4. Structure of SPARC (from Rolf A. 2000). The ribbon diagram derived from 
crystallographic data indicates three structural modules. The follistatin-like domain, aa 
53–137, is shown in red except for peptide 2.1, aa 55–74, and the (K)GHK angiogenic 
peptide, aa 114–130, which are shown in green and black, respectively. The EC-module 
(aa 138–286) is shown in blue except for peptide 4.2, aa 255–274, which is shown in 
yellow. 
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1.5.2. Expression of SPARC 
 
SPARC is expressed at high levels in bone tissue and is distributed widely in many 
other tissues and cell types, and is associated generally with remodeling tissues, e.g., 
tissues undergoing morphogenesis, mineralization, angiogenesis, and pathological 
responses to injury and tumor genesis. (Maillard, Malaval et al. 1992): Although 
SPARC-null mice are born without obvious abnormalities, targeted disruption of the 
SPARC locus in mice has shown that SPARC is important for lens transparency, as 
SPARC-null mice develop cataracts shortly after birth. A impaired wound healing in 
mice deficient in SPARC has been reported.(Basu, Kligman et al. 2001): Additionally, 
over expression of SPARC in nematodes also resulted in developmental 
abnormalities that included an uncoordinated (Unc) phenotype in the F1 generation. 
Furthermore, worms overexpressing SPARC did not produce any viable offspring 
(Schwarzbauer, Musset-Bilal et al. 1994): These results, and the data from SPARC-
null mice, indicate that the appropriate and regulated expression of SPARC is 
necessary for normal development. 
The expression of SPARC in the heart during fetal development is high, but 
after birth it is reduced and almost absent during adulthood.(Sage, Vernon et al. 
1989): In recent studies, the up-regulation of SPARC expression has been observed 
in the injured heart: Up-regulation of SPARC in the myocardium of adult rats has 
been seen during the remodelling of cardiac extracellular matrix during beta-
adrenergic stimulation.(Masson, Arosio et al. 1998): The increase of SPARC 
expression in the heart was reported in response to myocardial infarction as well 
(Stanton, Garrard et al. 2000): SPARC mRNA expression paralleled the up-
regulation of type 1 collagen mRNA after myocardial infarction implicating a role of 
SPARC in the process of scar formation. But so for, the protein levels of SPARC in 
heart have not been studied. The role of SPARC in the remodelling process in the 
heat is not clear. Interestingly, cardiac myocytes plated on fibronectin (FN) showed 
elevated expression of SPARC in vitro. Whether absence of SPARC may lead to an 
altered formation of collagen in the normal heart is unknown.  
 
1.5.3. Interaction of SPARC with other proteins 
Binding to cytokines is one of the major characteristics of SPARC. SPARC regulates 
the activity of at least three growth factors that are important for vascular 
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homeostasis .SPARC was shown to bind the PDGF (platelet –derived growth factor) 
dimers AB and BB, but not AA. PDGFs are a family of growth-regulatory molecules 
capable of inducing directed cell migration, proliferation and altered cellular 
metabolism. The specific interaction of SPARC with the B-chain prevented binding of 
PDGF to its receptors on smooth muscle cells. The affinity of SPARC for this 
important growth factor could regulate the availability of PDGF dimers and thus affect 
the biological response to PDGF and may consequently control proliferative repair 
processes. (Raines, Lane et al. 1992) That SPARC interacts with PDGF and inhibits 
cell proliferation induced by PDGF indicates the importance of SPARC in 
angiogenesis. Because both SPARC and PDGF are found in platelet α-granules, and 
expression of both proteins is elevated in atherosclerotic plaque and in models of 
kidney disease, it has been proposed that SPARC might regulate the activity or 
distribution of PDGF in vivo.(Floege, Alpers et al. 1992)  
In addition to PDGF, VEGF, and bFGF, SPARC can also modulate the activity 
of TGF-β. TGF-β is an important and widely-distributed growth factor, which is 
associated with the rapid remodeling of connective tissues and has been shown to 
regulate the expression of extracellular matrix proteins ((Kingsley 1994) SPARC can 
magnify TGF-ß1 expression (mRNA and protein) in cultured mouse mesangial cells 
(Francki, Bradshaw et al. 1999)SPARC-null mesangial cells also showed significantly 
decreased synthesis of TGF-ß1 mRNA, and addition of SPARC to SPARC-null cells 
in culture restored the expression of TGF-ß1 to levels typical of wild-type cells 
(Francki, Bradshaw et al. 1999). Given the coincidence of TGF-ß and SPARC in 
embryonic development and wound healing (Sage, Decker et al. 1989)the modulation 
of SPARC by TGF-ß and that of TGF-ß by SPARC are likely to be significant. On 
contrast, TGF-ß had been shown to regulate the expression of SPARC in fibroblasts 
(Lane and Sage 1994) Whether TGF-β1 and SPARC interact directly or not is 
unknown, but it is clear that both factors participate in a feedback loop that influences 
their production. There is considerable circumstantial evidence to indicate that 
SPARC interacts with TGF-β1and/or affects proteins of the TGF-β1 signaling 
pathway. 
It is known that SPARC binds to collagen, but the functional significance of the 
interaction of SPARC with collagen in tissues is not clear. Collagen may serve as a 
storage site for SPARC in the ECM or might directly modulate the activity of SPARC, 
e.g. its counteradhesive or anti-proliferative function. The fact that proteolytic 
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cleavage of SPARC results in a higher affinity for collagen indicates that collagen is a 
potentially important ECM ligand for SPARC.(Yan and Sage 1999): Interestingly, 
SPARC has been shown to increase the production and activity of MMPs 
(Shankavaram, DeWitt et al. 1997; Gilles, Bassuk et al. 1998):These results suggest 
that SPARC might participate in an autocrine or paracrine positive feedback loop. For 
example, SPARC stimulates the expression and activity of MMP-2 and in turn, MMP-
2 proteolytically cleaves SPARC, which increases the affinity of SPARC for collagen 
and presumably its localization to the basement membrane, an efficacious site for an 
anti-proliferative and counteradhesive protein 
 
1.5.4. Possible role of SPARC in the heart during stress and remodelling 
The matricellular protein SPARC shows an increased mRNA level in the heart in 
response to injury or stress, which suggests a critical function of SPARC in wound 
hearling and ventricular remodelling (Masson, Arosio et al. 2000; Stanton, Garrard et 
al. 2000; Komatsubara, Murakami et al. 2003). SPARC may modulate matrix 
remodeling and wound healing in the heart by different ways. First, SPARC may alter 
activity of growth factors, including TGF-β, bFGF, PDGF and VEGF, which are 
involved in wound healing after cardiac injury (Brekken and Sage 2000). Yan and 
Sage 1999), Secondly, SPARC induced de-adhesion may be involved in stimulating 
invasion of wound healing cells including fibroblasts, but also facilitating myocyte 
slippage and cardiac dilatation.. Finally, SPARC may modulate angiogenesis (Sage 
and Vernon 1994; Reed, Bradshaw et al. 2005)and might thereby influence infarct 
healing after myocardial injury. SPARC has been involved in ventricular remodeling, 
this alteration may due to the different mechanisms: 1) SPARC may initiate de-
adhesion between cardiomyocytes and the ECM, meaning the transformation from a 
strong cell–ECM adhesion to an intermediate cell–ECM adhesion, which allows cells 
to spread 2) SPARC might increase proteinases activity such as MMPs involved in 
cardiac remodeling and function in different cardiac diseases (Spinale 2002). 
Whether osteonectin up-regulation after cardiac injury or during hemodynamic 
stress may be beneficial or detrimental for cardiac structure or function requires 
further investigation. The study of the role of SPARC in the heart during stress and 
remodeling is just at the beginning, more research is still behind us … 
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1.6 Aim of this study  
 
1.6.1. The Matracellular protein SPARC has been shown to participate in a number 
of processes related to tissue repair, however, little is known about SPARC during  
myocardial remodeling. The present study was designed to clarify the contribution of 
SPARC in the remodeling process after myocardial infarction and aortic banding. 
 
1.6.2. Integrines mediate cell-cell and cell-matrix interactions that lead to intracellular 
signal transduction and wound heading, processes important in tissue repair. 
Following our study of SPARC expression in myocardium after injury, by using 
integrin β1 knockout mice and integrin αv inhibited mice, we further investigate an 
interrelationship between SPARC and integrins in MI and aortic banding mice, which 
may identify the mechanism involved in the healing of the infacted myocardium.   
 
1.6.3. Furthermore, SPARC can be secreted by a different type of cells including 
fibroblasts, but nothing was known about the expression of SPARC in 
cardiomyocytes.Therefore, the occurrence of SPARC expression in different cell 
types and the role of TGF will be studied. 
 
1.6.4. Finally, the function of SPARC in injured myocardium is still speculative. As a 
main function SPARC modulate cell migration by binding to ECM proteins. The 
influence of SPARC on ECM –induced migration of fibroblasts will be investigated.  
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2. Characterization of Cardiac specific excision of 
the β1 integrin gene in mice -  
influence on the transcriptional response after 
transversal aortic constriction  
 
Heart failure and pathological overgrowth of the heart often occur hand in hand. New 
data on a biomechanical sensor challenge the viewpoint that cardiac hypertrophy 
causes heat failure 
 
        (Barki-Harrington and Rockman 2003) 
 
 
 
2.1. Introduction 
   
Cardiac hypertrophy is an adaptive response to mechanical and hormonal stimuli. 
Arterial hypertension imposes the heart to work harder than under normal 
circumstances. Although the performance of the heart can be well-maintained in a 
wide range of physiological stressors increased biomechanical stress (from either 
exercise or disease) can drive morphological changes in the heart muscle, which is 
known as cardiac hypertrophy. Cardiac hypertrophy is an increase in mass of the 
heart primarily due to an enhanced cell size. This increase in heart mass and heart 
muscle strength is considered beneficial, because it allows the generation of greater 
contractile force, but -in parallel- it may result in activation of pathways that reduce 
the efficiency of structural adaptation, promoting the transition toward cardiac dilation 
and failure(Chien 1999). The molecular and cellular mechanisms, which drive the 
pathological transition from cardiac hypertrophy to cardiac failure has been the 
subject of intense investigation for over a half century. 
 Cardiac hypertrophic remodeling is triggered by a combined action of 
mechanical stretching of cardiac walls and activation of neurohumoral growth factors 
(Ruwhof and van der Laarse 2000). Signals originating from all these pathways 
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converge to promote cardiac hypertrophy, however, the mechanical sensor that 
initiates these responses is poorly understood. Transduction of mechanical stress 
into biochemical signals is usually mediated by a group of cell surface receptors 
called integrins, which link the extracellular matrix to the cellular cytoskeleton thus 
providing physical integration and signal transduction between the outside and the 
inside of the cell. This combination of properties allows integrins to play important 
roles in cell growth, differentiation, and survival. Also in the area of cardiovascular 
research, integrins perform essential roles in the developing and postnatal heart.  
Previous work in vivo and in vitro has provided a lot of evidence that integrins 
encompassing the β1 subunit are linked to the hypertrophic response. Ross et al 
demonstrated that ß1 integrin function is involved in the 1-adrenergic-mediated 
hypertrophic response of neonatal rat ventricular myocytes (Ross, Pham et al. 1998) 
whereas inhibition of  β1 function and signalling reduced the adrenergically mediated 
hypertrophy (Ross, Pham et al. 1998). 
Since the arrival of gene-targeting technology, not only can defined nucleotide 
changes be engineered into the genome of the mouse, but genetic switches can be 
designed to target expression or ablation of any gene to any tissue and any defined 
developmental period (Sauer 1998). Knockout mice models have proven to be 
elegant and powerful experimental models for answering questions about the 
function of individual gene products. However, ablation of many essential genes is 
lethal to mice, especially if the gene is needed early during development.As reported 
for β1 Integrin, the deletion of its gene in mice results in inner cell mass failure and 
peri-implantation lethality (Fassler and Meyer 1995; Stephens, Sutherland et al. 
1995). To study the effects of knockout genes without the problem of embryonic 
lethality, a clever genetic control system (Cre/lox) has been devised, which made it 
possible to disrupt genes only in a particular cell or tissue type (Gu, Zou et al. 1993; 
Chen, Kubalak et al. 1998; Hirota, Chen et al. 1999). To evaluate the role of β1 
integrins in hypertrophy development, we took advantage of Cre-loxP gene targeting 
system. This system is derived from bacteriophage P1 from E.coli (a circular 
lysogenic virus) and involves two components: the 38 kDa Cre site-specific 
recombinase and the 34 bp long Cre-specific recongnition sequences termed loxP 
(Hoess, Ziese et al. 1982; Abremski and Hoess 1984; Kilby, Snaith et al. 1993). The 
Cre enzyme catalyzes recombination between two loxP sites and, therefore, the 
gene of interest, in our case integrin β1, has to be flanked by two loxP sites and this 
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configuration is also referred to as a conditional “floxed” allele (Fassler and Meyer 
1995). Because the loxP sequences lie within introns and are only 34 bp in length, 
the floxed allele is predicted to function normally and, therefore, the expression level 
of the floxed allele is expected to be the same as that of the wild type. Crossing of 
the mice encoding the floxed allele with transgenic mice carrying the Cre 
recombinase gene under the control of a cell type-specific promoter, in our case the 
cardiomyocyte-specific myosin light chain-2v(MLC2v) promoter leads to the 
generation of  a ventricular-specific  integrin β1 knock out. The MLC2v gene is 
expressed bilaterally in the embryo in the cardiac primordia. Because of the restricted 
cardiac expression of this gene to the ventricles at the earliest stages of ventricular 
specification, Cre recombinase are chosed under the control of MLC2v regulatory 
elements. The Cre-loxP recombination system for the generation of conditional and 
tissue-specific knock-out mice is shown in Figure2.1. 
 
Figure 2.1. Cre-loxP recombination system for the Generation of Regulated Knockouts (Sauer 
1998).
C e l l - t y p e - s p e c i f i c  g e n e 
knockouts using the loxP-Cre
recombination system. Two 
loxP sites are inserted on each 
side of an essential exon (2) of 
the gene of interest (i.e., gene 
X)  (b lue )  by homo logous 
recombination. These sites do 
not disrupt gene function. The 
loxP-conta in ing  mouse is 
crossed to a transgenic mouse 
carrying a cell-type-specific 
promoter controlling expression 
of the Cre recombinase, which 
induces recombination between 
loxP si tes. This mouse is 
heterozygous for a constitutive 
gene  X knockou t .  In  the 
resulting loxP-Cre mouse, Cre
protein is produced only in 
t hose  ce l l s  i n  wh ich  the 
promoter is active, and in those 
cells recombination therefore 
occurs between the loxP sites, 
leading to deletion of exon 2. 
Since the other allele is a 
constitutive gene X knockout, 
deletion between the IoxP sites 
results in complete loss of 
function in all cells expressing 
Cre………..............................  
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It is known that ECM proteins are involved in the tissue remodeling that is 
observed during cardiac hypertrophy. Activation of integrins by different ligands in the 
ECM (e.g., collagen, fibronectin and vitronectin) (Giancotti and Ruoslahti 1999; 
Laser, Willey et al. 2000) initiates singnaling transduction pathways through integrin-
associated proteins that regulate gene expression, cell migration, growth and 
survival. However, knowledge concerning the function of Integrin β1 in the heart is far 
from complete. Little is known about the mechanisms how integrin β1 acts on ECM 
gene expression in heart after pressure overload, e.g. aortic banding. Integrin β1 is 
abundant in cardiac myocytes and is known to bind to collagen. In an effort to better 
understand the role of β1integrin in the pathogenesis of pressure overload-induced 
cardiac hypertrophy, the wild-type and β1 integrin knock-out mice were investigated 2 
days, 7 days, and one month after aortic banding. 
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2.2. Results  
  
2.2.1. Generation of heart-specific conditional β1-integrin knockout mice using 
the Cre-loxP system. 
 
By using the Cre-loxP strategy (Marth 1996), a specific ventricular myocyte-restricted 
inactivation of the β1 integrin gene was achieved in mice. In particular, we mated the 
homozygous floxed β1 integrin mice to MLC2v ("myosin light chain 2v"-driven 
promoter for cardiac specificity) Cre reconbinase ‘‘knockin’’ mice, which have been 
characterized previously (Chen, Kubalak et al. 1998; Hirota, Chen et al. 1999). The 
sketch of the Cre-loxP strategy (Figure 2.2) shows that Cre reconbinase-mediated 
excision would delete exon 2 (containing the translational start codon) and exon 3 of 
the β1 integrin gene. This excision event would prevent expression of all known 
splice variants downstream of these exons. 
In order to obtain the special heart conditional integrin β1 knock out mice two steps of 
interbreeding heterozygous mice were taken (shown in figure 2.4): firstly, we cross 
breeded the Cre reconbinase ‘‘knockin’’ mice (Cre+/-) and a conventional integrin β1 
heterozygous knock out mice obtained from Dr.R.Fässler (Max-Planck- Institute of 
Biochemistry, Martinstried, Germany) as shown in figure 2.3 (Fassler and Meyer 
1995) The offspring consisted four different genotypes. Mating the genotype mouse 
(Cre and integrin knock out double transgenic mouse: Cre+/-, β-/+) to the 
homozygous loxp-integrin mouse (Cre-/-, β c/c) will generate the final desired double-
transgenic mouse in which the loxp-integrin genes will be deleted in ventricular 
myocyte in which the cre transgene has been expressed. The schematic figure was 
shown in figure 2.3, that is in our study transgenic mice containing integrin β1 gene 
surrounded by loxP sites are mated with transgenic mice that have the cre gene 
expressing only ventricular myocytes; The resulting integrin β1 knock out mice (β-/+) 
will contain both the cre gene and the loxP-flanked site In tissues with no cre gene 
the target gene with be present and function normally. In the ventricular myocyte 
where Cre is expressed, the target gene of integrin β1 will be deleted. 
 
 
 
 
  
 Characterization of cardiac specific excision of the β1 integrin gene in mice  - 41 - 
 
 
E2 E3 E4 E5
E2 E3 E4 E5
Loxp Loxp
Cre mediation
Wild type
β1 Floxed
E4 E5
RI RI
RI
RI
RVRI
RI
β1 Deleted 
RV 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Schematic drawing of conditional integrin β1 knock out. Restriction 
map of wild-type, floxed, and deleted allele of the integrin β1 gene. Symbols are as in 
the figure. Triangles and rectangles present loxP sites and exons respectively. RI: 
EcoRI site, RV: EcoRV site. The recombined and non-recombined alleles could be 
discerned by EcoRI digestion-induced restriction length fragment polymorphism. Cre-
mediated recombination leads to deletion of exons 2 and 3 of the β1 integrin gene.  
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic drawing of the conventional integrin β1 knock out: 
disruption of the second exon of the β1 integrin gene in ES cells. Restriction map 
of the wild type allele, the targeting vector and the mutated allele of the β1 integrin 
gene as indicated. The geo-cassette was inserted in frame with the ATG. Restriction 
sites: B, BamHI; RI, EcoRI; RV, EcoRV.  
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Figure 2.3 Cre/lox Mouse breeding. In the first step, Mice with the Cre protein 
expressing in a specific cell type (ventricular myocyte) are bred with 
heterozygous integrin β1 knock out mice (Cre -/-, β+/-). The offspring with desired 
genotype’*’as indicated are further interbreeded with mice that contain a target 
gene integrin β1 surrounded by loxP sites. When the mice are bred, the cells 
(ventricular myocyte) carrying Cre will cause those cells to lose the target gene in 
the second step of interbreeding of heterozygous mice. The symbol ‘*’ as 
indicated is the desired mice, which is used for our study.   
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2.2.1.1. PCR analysis of genomic DNA 
 
Genomic DNA from the offspring of crosses between homozygous integrin β1 floxed 
animals and Cre-transgenic mice (figure 2.3) were screened by PCR for the deletion 
event of integrin β1. (Figure 2.4) the PCR products were obtained from genomic DNA, 
using 3 primer sets to detect Cre recombinase, integrin β1 knockout +/- and integrin 
β1 loxP(c/c). As expression of Cre recombinase was under control of the MLC -2v 
promoter, Cre expression and subsequent Cre-mediated excision only occurred in 
heart, whereas other organs such as liver, brain, spleen. Lung, kidney were not 
affected. This tissue and cell type specific action of MLC-2v-Cre was already 
demonstrated by a previous study  (Shai, Harpf et al. 2002). Specially, in our study, 
by interbreeding, the conventional integrin β1 knockout +/- mice contain transgenic 
gene cre+/- were cross bred with homogyous conditional integrin β1 loxP (c/c), the 
desired knock out mice are shown in the figure.   
  
   
 
Figure 2.3   β1 integrin gene knock out detection by PCR analysis. Ethidium bromide 
visualization of PCR products generated with genomic DNAs isolated from 10 mouse tail 
biopsies. PCR reactions were performed using 3 sets of primers and separated on a 2% 
agarose gel. One set of primers detected a 419 bp fragment of the Cre transgene, Cre+/- 
(upper panel). A second set of primers detected a 210-bp band β1conventional heterozygous 
integrin gene (middle panel). The 400 bp and 320 bp bands indicated the conditional loxp 
(β1c/c) and wild type mice (WT) sequences respectively (lower panel). No abnormal sizes 
were detected.lane 3 indicated the desired β1 integrin gene knock out. 
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2.2.1.2. Detection of β1 Integrin protein level in knockout mice  
 
The Integrin β1 subunit is expressed in multiple cell types, which are found in 
addition to cardiomyocytes in the ventricle. Indeed, only 14% of adult mouse 
ventricular cells are cardiomyocytes. However, muscle cells specifically express an 
isoform of β1, called β1D, which results from alternative splicing of the integrin β1 
gene. To analyse the cardiomyocyte-specific deletion of the integrin β1 gene, we 
determined the levels of integrin β1D in the mouse heart by Western blot. 
Accordingly, hearts of β1 integrin knock out mice (MLC2v-Cre+/- β1 floxed c/-) at the 
age of one month, three months was extracted. As shown in Figure 2.4, Integrin β1D 
expression was reduced to about 35 %±3.4 and 12%±1.9 of the control levels, 
respectively (n=6 each group, p<0.001).  
This result conformed the integrin β1 Knock out mice at protain level expression.   
 
 
 
 
Figure 2.4 β1 integrin protein expression in knock out mouse. Densitometric analysis 
of Western blots showed that the normalized β1D Integrin protein (top panel) in heart of 
β1 integrin knock out mice (Cre+/-, β1-/C) at the age of one month or three months were 
reduced to 35 %±3.4 and 12%±1.9 of the control levels of wild-type animals (WT),  Data 
are arbitrary densitometric units of β1 integrin protein normalized to GAPDH. (n=6 each 
group, *p<0.001) 
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2.2.2. Physiological alterations after aortic banding in mice  
 
2.2.2.1. Enhanced mortality in  integrin β1 knock out. 
 
Mortality rate over one month observation period were higher in integrin β1 knock out 
than in wild type mice following aortic banding (AB) (knock out-AB 55% versus WT-
AB 12% at day 2 after AB; knock out-AB 65% versus WT-AB 14% at day 7 after AB; 
knock out-AB 75% versus WT-AB 18% at one month after AB. Deaths in sham-
operated mice (n=1 in KO sham. n=0 in WT sham group) occured in a single case 
during the surgery, which may due to lower anesthesia tolerance, but no post-
surgical mortality was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2.5. Mortality after aortic banding (AB). Cumulative mortality rates of β1 
integrin knock out and WT mice after AB or sham-operated as observed at day 2, day 
7 and one month after surgery. Mortality rates were higher in group o f AB knock out 
mice than in WT-AB (n=12 for each group).  
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2.2.2.2. Morphometry  
Tab1 Morphometric data 
 
Parameter           
    WT      KO   
 sham   AB   sham   AB  
 (n=18)    (n=20)   (n=19)   (N=21)
 
Body weight, g      
AB-2d  27.1 ± 1.1  27.2 ± 2.8  28.2 ± 3.3  25.2 ± 2.2 
AB-7d  28.3 ± 2.2  27.2 ± 3.3  27.8 ± 3.8  22.6 ± 3.4# 
AB-1m  27.8 ± 3.2  28.1 ± 3.3  27.1 ± 3.4  23.1 ± 3.9# 
 
Lung weight, mg  
AB-2d  148.8 ± 11.8  196.7 ± 23  168.9 ± 24.3  192.8 ± 24 
AB-7d  149.8 ± 12.8  211.2 ± 21*  172.9 ± 34.3  246.0 ± 30* 
AB-1m  148.6 ± 11.7  295.3 ± 45*  194.9 ± 14.3*  248.3 ± 36* 
 
Lung weight/Body weight     
AB-2d  5.2 ± 0.5  8.6 ± 1.4  6.8 ± 0.9  7.8 ± 1.2   
AB-7d  5.3 ± 0.5  7.4 ± 0.6  5.8 ± 0.8  11.2 ± 1.6*# 
AB-1m  5.2 ± 0.4  10.2 ±1.6*  6.8 ± 0.6  11.0 ± 0.9*
           
Heart weight, mg     
AB-2d  135.1 ± 5.8  122.9 ± 3.8  140.2 ± 6.5  122.4 ± 9.9 
AB-7d  137.1 ± 4.8  171.2 ± 10.3*  141.2 ± 5.5  155.6 ± 6.9 
AB-1m  130.1 ± 5.7  203.8 ± 7.0*  139.2 ± 6.4  159.7 ± 9.6# 
 
Tibia length, mm     
AB-2d  18.3 ± 0.1  18.1 ± 0.2  18.4 ± 0.4  18.1 ± 0.1 
AB-7d  18.3 ± 0.1  18.1 ± 0.1  18.3 ± 0.2  18.4 ± 0.2 
AB-1m  18.2 ± 0.1  18.0 ± 0.2  18.7 ± 0.2  18.5 ± 0.2 
             
Heart weight/Tibia length     
AB-2d  7.3 ± 0.3  6.8 ± 0.3  8.1 ± 0.8  6.8 ± 0.6 
AB-7d  7.2 ± 0.2  9.1 ± 0.5*  7.9 ± 0.3  8.3 ± 0.4 
AB-1m  7.1 ± 0.1  10.9 ± 0.4*  8.2 ± 0.3  8.7 ± 0.5 
 
Statistically significant differences between sham-operated and aortic banded mice of each group are 
indicated. All measurements were performed 2 days (2d), 7 days (7d) and 1 month (1m) after aortic 
banding or sham operation. The data were included after AB only when pressure gradients between 
left and right carotid are higher than 30 mmHg. *p< 0.05 AB vs sham; #P<0.05, KO-AB vs WT-AB. 
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Seven days after AB and after one month, body weight was significantly reduced in 
knock out mice as compared to wild-type control mice (7d:KO-AB 22.6±3.4 g vs. WT-
AB 27.8±3.8 g, p<0.05; one month: KO-AB 23.1±3.9 g vs. WT-AB 28.1±3.4g, p<0.05). 
Lung weight and lung weight to body weight ratios were significantly increased in 
both groups and to a comparable extent after aortic constriction. The absolute gain in 
heart weight and heart weight to tibia ratios, which were significantly higher in AB-WT 
mice than in AB-KO mice at day 7 and one month after aortic banding (p<0.01). 
However, this increase was not observed in knock out mice after AB as compared to 
control group at any time point studied 
. 
2.2.2.3. Transthoracic Echocardiography in the beta-1 knock out Mouse   
Echocardiograms, among the most widely applicable technologies in clinical 
cardiology, have been adapted for non-invasive physiologic studies in mice (Tanaka, 
Dalton et al. 1996; Pelzer, Loza et al. 2005). Echocardiograms are particularly useful 
because they can provide a generalized picture of the structure and function and of 
the heart throughout the life of the specimen. M-mode echocardiography provides 
quantitative data about contractile function. The analysis of echocardiograph is the 
procedure most often used in mouse studies. It is optimized for higher sample 
frequency and smaller heart size to accommodate the mouse´s diminutive size and 
resultant rapid heart rate. 2 days, 7 days and one month after AB, the consequences 
of the experimentally sustained pressure overload on LV morphology and function 
were non-invasively assessed using echocardiography. The data from these 
procedures provided a detailed and holistic view of cardiac function. Data 
comparisons from wild type and beta 1 knock out mouse with or without aortic 
banding were used to understand the effect of the genetic alteration in the heart 
pressure overload model in the context of the whole heart function. Data were shown 
in table 2. 
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Table 2 
 Echocardiography measurements after surgery  
 
  WT   KO   AB-WT  AB-KO
  n=20    n=19   N=21   N=18
 
HR, bmp        
AB-2d  445 ± 18  508 ± 49  401 ± 28  490 ± 21 
AB-7d  455 ± 16  511 ± 49  440 ± 34  500 ± 43 
AB-1m  438 ± 28  522 ± 24  450 ± 10  510 ± 39 
 
IVS,mm          
AB-2d  0.80 ± 0.03  0.78 ± 0.09   0.79 ± 0.06  0.78 ± 0.05  
AB-7d  0.81 ± 0.03  0.77 ± 0.04   1.38 ± 0.01*  0.72 ± 0.10# 
AB-1m  0.80 ± 0.02  0.78 ± 0.07  1.63 ± 0.14*  0.91 ± 0.12#
           
PWTh,mm      
AB-2d  0.79 ± 0.08  0.85 ± 0.17  0.82 ± 0.08  0.86 ± 0.13 
AB-7d  0.80 ± 0.06  0.84 ± 0.27  1.21 ± 0.17*  0.89 ± 0.09 
AB-1m  0.79 ± 0.05  0.87 ± 0.19  1.38 ± 0.12*  0.90 ± 0.11 
 
LV%FS       
AB-2d  37 ± 3.1  28 ± 2.9  33.2 ± 2.5  29.2 ± 3.5 
AB-7d  38 ± 2.1  30 ± 2.7  44.1 ± 4.3  19.4 ± 4.2*# 
AB-1m  35 ± 3.7  27 ± 3.0  30.2 ± 2.2  12.6 ± 4.8*# 
 
All measurements were performed 2days (2d), 7 days (7d) and 1 month (1m) after aortic banding/ 
sham operation.  HR, heart rate; IVS, interventricular septum; PWTh, end-diastolic posterior wall 
thickness; LV%FS, fractional shorting *p< 0.05 vs WT sham; # P<0.05 vs WT-AB 
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Fig 2.6. Value of LV fractional shortening (FS). FS in knock out and wild type mice after 
AB or sham operations at different time points. Bars represent the values of two 
independent experiments. Open bars and close bars indicate wild type and knock out mice, 
respectively. FS was significantly reduced in AB-knock out mice as compared to sham 
operated at day 7 and one month after AB. In both groups, no significant changes were 
observed two days after aortic banding as compared to sham-operated animals (n=6 for 
each group, *P<0.01 versus sham operated. # p<0.01 wild type versus knock out mice).   
 
As compared to sham-operated mice, there were no significant changges of heart 
rates in both genotypes after AB. In contrast to corresponding sham-operated mice, 
LV fractional shortening (FS) was significantly reduced in knock out mice at day 7 
and 1 month after AB, whereas, there were no significant changes in wild type mice 
at any of the time pointes tested in our study. The reduction of FS in AB-knock out 
mice was significantly reduced than that in AB-wild type mice (Fig 2.6) In both 
genotypes, IVS (interventricular septum), PWTh (end-diastolic posterior wall 
thickness) and FS (LV fractional shortening) did not differ significantly between 
sham-operated and AB 2 d post-surgery. 7 d and one month after AB, significant 
increases of IVS and PWTh were seen in wild type but not in knock out mice. 
Together with the morphometric data (no increase of heart weight to tibia ration in 
knock out mice after AB) showed  that overload-induced heart hypertrophy occurs in 
wild-type mice but not in knock out mice (Fig 2.6). 
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Fig2.7. Morphometry and Echocardiography. Parameters indicate a hypertrophic 
response induced by pressure overload (aortic banding) in mice. A: heart weight/tibia length 
ratio was significantly increased in AB-wild-type hearts vs. sham-operated hearts (n=12 for 
each group, *p<0.05.)  B: After AB, wall thickness was statistically increased in wild type 
versus sham-operated hearts (n=5 for each group, *p< 0.05). Open bar indicated wild type 
and close bar indicated knock out mice. 
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2.2.2.4 Hemodynamic analyses  
Table 3: 
Hemodynamic data in WT and integrin beta-1 knock out mice.  
 
  Ctr-WT  Ctr-KO   AB-WT  AB-KO  
   n=20   n=19   n=21    n=18
 
HR, bmp        
AB-2d  505 ± 12  526 ± 11  533 ± 28  478 ± 66 
AB-7d  504 ± 23  532 ± 18  501 ± 26  482 ± 65 
AB-1m  497 ± 33  551 ± 23  466 ± 21  475 ± 41 
 
Systolic blood pressure, mmHg       
AB-2d  124 ± 10  122 ± 9  106 ± 14  117 ± 9  
AB-7d  111 ± 11  112 ± 9   123 ± 10  109 ± 3 
AB-1m  134 ± 12  132 ± 10  120 ± 14  128 ± 11
        
LVEDP, mmHg    
AB-2d  4.5 ± 0.5  4.0 ± 1.1  5.3 ± 0.6  6.1 ± 1.8 
AB-7d  4.6 ± 0.5  4.5 ± 0.8  8.2 ± 0.6*   6.0 ± 1.7 
AB-1m  4.8 ± 0.4  4.3 ± 1.1  10.6 ±1.6*  3.9 ± 1.0*# 
 
dp/dtmax         
AB-2d  8041 ± 584  7980 ± 511  4266 ± 705  5800 ± 741* 
AB-7d  7998 ± 465  7988 ± 415  9675 ± 442*  5239 ± 331# 
AB-1m  8061 ± 345  8034 ± 389  10300 ± 452*  4001 ± 345#
       
dp/dtmin      
AB-2d  5418 ± 453  7244 ± 809  4800 ± 613  4806 ± 809 
AB-7d  5423 ± 342  6987 ± 769    666 ± 518  4066 ± 731 
AB-1m  5922 ± 453  6244 ± 812  4000 ± 339  4700 ± 454
 
Table 3. All measurements were performed 2days (2d), 7 days (7d) and 1 month (1m) after aortic 
banding/ sham operation. The data were included after AB only when gradients between left and right 
carotid are higher than 30 mmHg LVEDP indicates LV end-diastolic pressure, dp/dtmax velocity of 
systolic LV pressure devepment; dp/dtmin velocity of diastolic LV relaxation.*p< 0.05 vs WT sham; 
#P<0.05 vs WT-AB. 
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The consequences of the sustained pressure overload on LV morphology and 
function were also invasively assessed using a 1.4 F conductance catheter. No 
significantly differences in either systolic blood pressure or heart rate were detected 
in knock out and WT mice after AB. LV end-diastolic pressures (LVEDP) were 
increased at day 2 and elevated further one month after AB, whereas the LVEDP of 
knock out mice did not differ from the corresponding sham mice at day 2 and day 7 
after AB. Furthermore, a reduction of LVEDP of knock out mice one month after AB 
was observed. Values for LV dp/dtmax were increased significantly in wild type mice after 
AB as compared to sham operated mice, on the contrast, the values were significant reduced 
in knock out mice after AB as compared to WT-AB. However, there were no significant 
differences in the values for LV dp/dtmin among the treated and untreated groups. There were 
no significant differences in these parameters among any of the time points of sham 
operated mice. 
 
2.2.3. Effect of absence of β1-Integrin on SPARC gene expression after AB  
2.2.3.1. SPARC gene expression was modulated  
Most forms of cardiac hypertrophy are accompanied by changes in gene 
expression.(Stanton,L. W.,L.J. Garrrard, et al. 2000) Fig 2.8 shows that deletion of 
integrin β1 in mouse hearts modulated the expression profile of several genes 
following aortic banding. One of the strongly upregulated transcripts is coding for the 
matrix protein SPARC (secreted protein, acidic and rich in cysteine), also known as 
Osteonectin or MB-40). The location of SPARC is indicated by a circle in Figure 2.7. 
The expression of the employed positive controls β-actin (111,112), GAPDH 
(103,104), CyclophilinA (105, 106, 107,108) and ribosomal protein L13a (109,110) 
remained constant in both groups, independently of the presence or absence of 
Integrin β1. The total layout of the gene array is shown in Fig 2.8. In wild-type 
animals, the mRNA level of SPARC was significantly increased at day 2 and elevated 
further at day 7 and one month after AB, whereas the up-regulation was deprived in 
integrin knock out animals. Most of the genes of ECM were increased after AB as 
also shown previously (Tran, Lu et al. 2004), (Chen, Huang et al. 2004). Surprisingly, 
some well-characterized genes, such as MMP, were not detected in these analyses. 
The failure of detection by the microarray assay might be due to the limited sensitivity 
of the used cDNA microarray (Detisi, J 2000).  
 Characterization of cardiac specific excision of the β1 integrin gene in mice  - 53 - 
 
 
 
 
 
 
 
Figure 2.8 Representative expression profiles and comparison of ECM/integrin-
related genes in mouse heart ventricle. Gene expression detected by cDNA 
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expression array system. Circle indicated SPARC gene. RNA was extracted from heart 
ventricles of the following groups of mice: sham-operated wild-type and knock out 
animals as control at different time point. Total RNA (5µg/membrane) was reverse-
transcribed and labeled with biotin and gene expression levels were detected using 
Nonrad-GEArray Q series kit and LPR kit. All positive controls showed a clear 
hybridization signal, whereas blanks and negative controls consistently showed the 
absence of any hybridization signal. Membranes were hybridized with labeled RNA 
previously isolated from individual animals. Shown are representative membranes 
hybridized with RNA isolated from a sham operated animal or knock out animals at AB 
day 2, day 7 and one month as indicated.  
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Figure 2.9. Distribution of genes in mouse heart chip. The chip encompasses 96 genes 
that encode cell adhesion and extracellular matrix proteins. These proteins play key roles in 
mediating cell-cell, cell-tissue and cell-extracellular matrix interactions. The PCR fragment of 
each gene was printed on a Nytran+ membrane with rectangular area of 23x35 mm.There are 
96 spots including blanks: (100-102), negative control: PUC18DNA (97-99), positive control 
genes: glyceraldehyde-3-phosphate dehydrogenase (103,104); cyclophilin A (PPIA) (105-
108), ribosomal protein L13a (109,110) and beta-actin (111, 112).  
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2.2.4. Altered protein expression  
  
2.2.4.1. Increased integrin β1expression  
 
Previous data have shown that Integrin β1 participate in the hypertrophic response of 
rat ventricular myocytes. Our study (Figure 2.10) demonstrated that in wild-type 
animals, integrin β1 is significantly increased at day 2 following aortic banding 
(1.8±0.08-fold, p<0.05 and was further elevated at day 7 (2.4±0.1-fold, p<0.05) as 
compared to sham-operated animals. In contrast, only sparse integrin β1 expression) 
was observed in knock out mice. 
 
2.2.4.2 Induction of SPARC 
 
Because up-regulation of SPARC gene was observed on the mRNA level and this 
induction was abolished in knock out mice, we further investigated the regulation of 
SPARC protein level by Western blotting. SPARC protein expression was 
investigated in mouse hearts following aortic banding at day 2 and day 7. Following a 
pattern very similar to that observed for integrin β1, SPARC protein levels were 
increased at day 2 (1.6±0.14-fold) and reached a significant difference at day 7 
(2.2±0.18-fold, p<0.05) after AB. This induction was abolished in integrin β1 knock 
out mice (Fig 2.9). 
 
 2.2.4.3.Pro-ANP Expression in the left ventricle 
 
Furthermore, the amount of atrial natriuretic peptide (ANP), a marker for the severity 
of heart dysfunction and predictive for patients survival (Daugaard, Lassen et al. 
2005; Pelzer, Loza et al. 2005) were investigated by Western blots. In wild-type mice, 
a significant increase of pro-ANP was observed 2 d and 7 d after AB (2.8±0.15-fold, 
p<0.05 and 4.4±0.21-fold, p<0.05) as compared to sham-operated control mice. 
Interestingly, ANP expression was already significantly up-regulated in sham-
operated knock out mice as compared to sham-operated wild-type mice but aortic 
banding did not strongly influence the ANP expression in these animals. 
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Figure 2.10 Modulated protein expression following aortic banding. The expresson of integrin β1, 
SPARC and ANP was analysed by Western blot. Detection in cardiac protein extracts from mice 
hearts was performed using specific antibodies for Integrin β1 SPARC and ANP. Open bars and close 
bars represent wild-type and knock out mice as indicated. The intensity of the bands from total of 5 
mice per group was measured and relative intensity was calculated. *P<0.05 versus sham-operated.  
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2.3. Discussion  
 
The investigation reported here support the hypothesis that integrin β1 is necessary 
for the development of heart hypertrophy in response to pressure overload in mice. 
This is the first study to suggest interplay between integrin and SPARC in heart 
remodeling. The major mew findings of this study are that mice with a ventricle-
specific integrin β1 knock out exhibit impaired hypertrophic response after chronic 
pressure onveload (compared with WT), and that the lack of integrin β1 is associated 
with decreased induction of the ECM protein SPARC. 
 To circumvent the early embryonic lethality of the conventional integrin β1 
gene deletion strategy (Fassler and Meyer 1995), we have generated the mice by 
using the Cre loxP-system. As the Cre expression was restricted to the heart by the 
myosin light chain-2v promoter (Chen, Kubalak et al. 1998). the mice survived to 
adulthood. Soon after birth, some Integrin β1 was still present, because of incomplete 
Cre-mediated recombination in the hearts of these mice. However, most of the knock 
out mice could not survive longer than 6 months, due to a heart failure which is in 
agreement with another work, in which another strategy to achieve heart-specific 
deletion of the β1 gene has been used (Shai, Harpf et al. 2002). It might be that 
further reduction of Integrin β1 protein in the cardiac myoctes (reduction of integrin β1 
in our knock out mice was shown in figure 2.4) below a “not yet identified limited 
level”, could lead to an abnormal cardiac development and a final heart failure.  
 Compensatory hypertrophic response, as measured by increased either HW-
to BW ratio or HW-to tibia ratio was increased after aortic banding in wild-type mice 
and differed significantly at day 7and after one month, whereas this response was 
not observed in integrin β1 knock out mouse. Similar results were obtained by 
echocardiography showing as well that left ventricular wall thickness significantly 
increased at day 7 and after one month after aortic banding in wild type but not in 
knock out mice (data shown in Figure 2.7). The findings in our knock out mice are 
similar to melusin (a muscle-specific β1 integrin-interactin protein, that interacts with 
the integrin β1 cytoplasmic domain, has been demonstrated that response to 
mechanical overload) null mice, in which lack of melusin resulted in blunted 
hypertrophic response to pressure overload (Keller, Shai et al. 2001). In line with our 
results, which indicated that Integrin β1 is necessary to the development of 
hypertrophy in response to hemodynamic overloading. In addition, ANP,regarded as 
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“a hypertrophic maker” (Holtta, Happonen et al. 2001), the induction of Pro-ANP 
expression (linear regression analysis revealed a significant correlation between ANP 
serum levels and ventricular pro-ANP expression (Pelzer, Loza et al. 2005)) after 
aortic banding was observed in wild-type mice, consistent with the activation of ANP 
gene expression as described previously (Abbate, Biondi-Zoccai et al. 2002). 
However, the difference of ANP expression was abolished in integrin β1 knock out 
mice. Interestingly, although no significant difference of pro-ANP expression levels 
between sham-operated knock out and aortic banding knock out mice, a significant 
up-regulation of pro-ANP in sham-operated knock out mice was observed as 
compared to sham-operated wild type mice. In our study, no evidence of hypertrophy 
in β1 integrin knock out mice was observed. The data presented here suggested that 
cardiac hypertrophy and an increase in ventricular expression of ANP are not 
necessarily correlated. However, up-regulation of ANP in knock out mice pointed 
towards an existing chronic cardiac abnormality in their hearts. This was supported 
by the observation that the β1 KOs did not reach their normal life-span and died due 
to a heart failure.  
Interaction of ECM proteins with Integrins is proposed to play an important role 
in cardiac myocyte interaction and myocardial hypertrophy. β1 Integrin is a critical 
component of the linkage between the extracellular matrix and cytoskeleton. In the 
heart, the dominant postnatal isoform of β1 integrin is β1D, it is 5-10 times more 
strongly expressed in the heart than in skeketal muscles. Because the myocardium is 
subject to continuous mechanical stress, we analysed heart integrin β1D expression 
after aortic banding. Data showed an up-regulation at day 2 and day 7 in wild-type 
mice, suggesting an association of this protein with hemodynamic pressure 
overloading. In parallel with integrin β1 expression, we observed the same pattern of 
increased SPARC expression at day 2 after aortic banding, and further elevated at 
day 7 and one month. The increased RNA levels of SPARC has been shown in 
response to β-adrenergic stimulation of cardiac hypertrophy in hearts of rats (Masson, 
Arosio et al. 2000). Interestingly, the induction of SPARC in our knock out mice was 
abolished either on RNA level or on protein levels. SPARC is a multifunctional protein 
belonging to extra cellular proteins. (Sage, Vernon et al. 1989) It has been found to 
be expressed after tissue injury, to modulate ECM deposition and to inhibit cellular 
adhesion and spreading on collagen matrix (Sage and Bornstein 1991; Lane and 
Sage 1994). The role of SPARC in the injured adult heart is still speculative, but its 
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anti-adhesive properties may contribute to a loosening of ECM organization, 
facilitating the migration of immune cells to the site of injury, Cardiomyocyte 
hypertrophy, and matrix re-arrangement. Our data suggests an Integrin-dependent 
SPARC induction and function in the remodeling after heart injury.  
What could be the function of the Integrin β1 in the development of 
hypertrophy? Ventricular hypertrophy is an important adaptive mechanism to 
maintain the heart`s output. Investigators have shown an altered modulation of 
Integrin expression and extracellular matrix proteins in the hypertrophied myocardium 
(Pelouch, Dixon et al. 1993; Farhadian, Contard et al. 1995; Nebe, Rychly et al. 1995; 
Yamazaki, Komuro et al. 1995). This is particularly noteworthy and indicated that 
Integrins work as mechanotransducers, translating mechanical signals to biochemical 
signals (Ingber 1991; Nebe, Rychly et al. 1995). Thus Integrin might play a role in the 
translation of increased mechanical stress into the cardiac cell in response to stress. 
Interestingly, hypertrophic response to Angiotensin II was not different in WT and 
Melusin (Integrin β1-interacting protein) null mice (Kim, Dalal et al. 2000). This 
indicated that biomechanical stress attribution to pressure overload is different from 
that of neurohumoral-induced cardiac hypertrophy. Additionally, in light of our study, 
the interplay of Integrin β1 and SPARC was involved in the remodelling of heart injury. 
It was known that SPARC induces matrix metallo-proteinases (MMPs) such as 
Gelatinase B, sStromelysin, and Collagenase, which support immune cell invasion. 
MMPs are linked to the remodelling that occurs during the development of 
hypertrophy, and thus, it is possible that alterations in these molecules may also be 
present in our knock out mice. Appropriate linkage of ECM and cytoskeleton through 
β1 Integrins is essential for the development of compensatory hypertrophy. When β1 
integrin is reduced at the cell surface, this linkage is disrupted.   
In summary, we have produced a hemodynamic overload model with cardiac-
specific Integrin β1 deficiency resulting in abnormal response to pressure overload. 
Using this knock out model, we demonstrated the modulation of SPARC in different 
genotype mouse. However, the direct roles, which β1 Integrin and SPARC play in the 
hypertrophic response pathways in myocytes is presently unknown and needs to be 
explored further.  
 
 
 
  
 
 
 
 
 
Chapter 3 
 
Transient expression of SPARC in response to 
myocardial infarction in mice 
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3. Transient expression of SPARC in response to 
myocardial infarction in mice  
 
Myocardial infarction is the most common cause of cardiac morbidity and 
mortality in many countries, and left ventricular remodeling after myocardial 
infarction is important because it causes progression to heart failure 
            
         (Harada, Qin et al. 2005) 
 
 
3.1. Introduction  
 
Following myocardial infarction, the injured heart tissue undergoes a process of 
wound healing and scar formation, which is necessary to maintain structural and 
functional integrity of the organ. The preservation of cardiac function depends in part 
on the invasion of cardiac fibroblasts as well as restructuring of the extracellular 
matrix (ECM). In particular, deposition of ECM proteins such as collagen, fibronectin, 
and vitronectin at the infarcted area is thought to replace necrotic myocytes and 
leads to scar formation.  
In addition to classical ECM proteins, a number of so-called matricellular 
proteins has been described. Their role in cell adhesion and extracellular matrix 
remodeling is less well defined, but they seem to act as modulators of cell-ECM 
interactions. Prototype examples of matricellular proteins include thrombospondin 
(TSP)-1,TSP-2, tenascin C, osteopontin and also SPARC (secreted acidic protein 
and rich in cysteine) (Schellings, Pinto et al. 2004). Studies in SPARC knockout 
mice indicate that these proteins influence the wound healing response and play 
critical regulatory roles in tissue renewal(Bradshaw, Reed et al. 2002). SPARC, also 
known as osteonectin or BM-40, is an extracellular Ca2+-binding glycoprotein that 
promotes de-adhesion of cells from the matrix and influences migration, proliferation, 
shape and motility of cultured cells(Funk and Sage 1993) High levels of SPARC 
expression are observed during tumor growth(Bornstein and Sage 2002) and after 
tissue injury(Lane and Sage 1994)our recent studies using hemodynemic overload 
animal model in a heart specific integrin β1 knock out mice have indicated an 
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increased expression of SPARC in the myocardium after injury or stress, this is in 
line with other studies (Masson, Arosio et al. 1998; Komatsubara, Murakami et al. 
2003; Simkhovich, Kloner et al. 2003). Furthermore, this increased expression 
depending integrin β1 function was observed in our study. Integrins are the main 
family of cell surface receptors that sense the composition and structure of the ECM 
(Shai, Harpf et al. 2002). The cross talk of integrin and SPARC studied in some 
investigate showed that   SPARC is able to promote prostate cancer cell migration 
and this activity of SPARC is functionally connected to integrins αvβ3 and αvβ5(De, 
Chen et al. 2003). SPARC protein induction through β3 integrin expression has been 
reported (Sturm, Satyamoorthy et al. 2002). These findings suggest that wound 
repair are influenced by an interplay between integrins, including αv and the 
matricellular protein SPARC. However, the potential role of SPARC in the 
myocardium is still speculative and how SPARC expression and function are 
integrated into the ECM remodeling events following myocardial infarction is 
currently unknown. 
In the present study we investigated altered gene expression of ECM proteins and 
SPARC in response to experimental myocardial infarction in the mouse. We followed 
the hypothesis that SPARC is involved in ECM remodeling and myocardial infarction  
 
3.2. Results  
 
2.2.1. Gene expression events following experimental myocardial infarction  
 
Remodeling of the extracellular matrix and scar formation at the infarcted area is the 
key to compensate for lost cardiomyocytes and to sustain proper heart function. To 
analyse gene expression events concerning extracellular matrix proteins and the 
respective cellular receptors and regulators, we compared heart muscle transcript 
levels of sham operated animals to the RNA levels observed after experimental 
myocardial infarction by the help of GEArrayTM cDNA macroarrays. Gene expression 
profiling was performed on the ligation of the descending branch of the left coronary 
artery (LAD)-induced myocardial infarction and sham-operated mouse heart. 
(figure3.1). The distribution of the gene fragments, positive, negative controls and 
the complete gene list are available at www.superarray.com.The use of 
Ampolabeling-LPR derived probes provides more accurate and sensitive gene 
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expression profiling results in our cDNA macroarrays. The expression levels were 
analyzed and shown as -fold intensity in comparison with sham operated samples 
displayed in Table 1 and Table 2. The used arrays encompass 96 cDNAs encoding 
cell adhesion molecules, extracellular matrix proteins, and additional proteins that 
play central roles in cell-extracellular matrix interactions as well as tissue 
remodelling. Upon total RNA isolation from individual heart tissues at 2 or 7 days 
after the intervention, mRNA was reverse transcribed using gene specific primers in 
the presence of biotin-labeled UTP before hybridization to the array and signal 
detection. Following normalization of individual hybridization experiments, the 
expression levels in infarcted hearts were compared to sham operated samples. 
Whereas none of the analysed 96 genes showed significant down-regulation during 
the course of the study, a total of 14 genes were found to be induced more than 1.8-
fold after myocardial infarction two days (Table 1) and 23 genes were increased 
more than 1.8-fold at day 7 of myocardial infarction. (Table2). As indicatiors for 
successful myocardial infarction and induction of cardiac remodeling, collagen and 
fibronectin were strongly up-regulated. Beside several ECM genes, a prominent 
induction was observed for the matricellular protein SPARC (secreted protein acidic 
and rich in cysteine; also known as osteonectin and BM-40). Expression of SPARC 
was significantly increased after 2 days (2.65±0.24 fold, p<0.01) and 7 days 
(3.78±0.11 p<0.01) following myocardial infarction. 
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Figure 3.1 Representative gene expression profile in mice heart after myocardial 
infarction 7 days. . A total of 112 cDNA fragments (400bp in length) were arrayed in an 
18x16 format including 96 spots representing extracellular matrix proteins, integrins, 
proteases and related genes. 6 spots (Negative control including blanks), 4 spots (positive 
control), and the 2 spots encoding the house-keeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) used for normalization are indicated. All positive and house-
keeping genes show a clear hybridization signal, All bland spots and negative controls 
consistently show the absence of any hybridization signal. Glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) were chosen as positive controls and spotted on the bottom of the 
chip GAPDH were chosen as house-keeping genes. Membranes were hybridized with RNA 
isolated from individual animals. For the full layout of the array see fig 2.9. 
 
 
 
 
 
 
 
.  
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Table 1: Differential expression of genes in mouse hearts 2 days after experimental myocardial 
infarction (MI).
 
Spot location   Gene name                         fold induction  
            (MI versus sham operated) 
   n=6 
 
Cell adhesion molecules 
 39 Integrin alpha 7   1.88 ± 0.26   
 75 NCAM    3.77 ± 0.71    
 95 VCAM-1    2.31 ± 0.30    
Extracellular matrix proteins 
 20 Collagen 1a1    5.59 ± 1.45    
 31 fibronectin    2.01 ± 0.45    
 87 SPARC   2.65 ± 0.24    
   96 vitronectin   1.82 ± 0.44    
Proteases 
 4 caspase-8   2.35 ± 0.34   
  25 Cathepsin D   1.80 ± 0.26    
 57 Hyaluronidase   2.05 ± 0.45    
 60 MMP12   1.88 ± 0.23    
 79 uPA  2.88 ± 0.46    
Protease inhibitor 
 92 Timp1    9.83 ± 1.57 
  93 Timp2    2.25 ± 0.54*  
 
 
The listed genes displayed on average a more than 1.8-fold difference between the sham-operated 
and the infarcted animals 2 days after the intervention. The expression levels are shown as -fold 
increase compared to sham operated samples after normalization using the internal control (GAPDH). 
Values represent mean ± SEM of independent hybridizations of RNA isolated from 6 animals for each 
treatment for each time point 
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Table 2, Differential expression of genes in mouse hearts 7 days after experimental myocardial 
infarction (MI)..  
Spot location   Gene name  fold induction 
                 (MI versus sham operated)  
           (n=5) 
 
Cell adhesion molecules 
 17 CEACAM 1    4.73 ± 0.51 
 36 Integrin alpha 4    6.90 ± 1.97 
 38 Integrin alpha 6    2.03 ± 0.30 
 39 Integrin alpha 7    3.69 ± 1.12 
 40 Integrin alpha 8    3.36 ± 0.05 
 45 Integrin alpha x    3.05 ± 0.39 
 81 ELAM-1    4.26 ± 0.20 
 75 NCAM    4.40 ± 1.57 
 95 VCAM-1    2.95 ± 0.35 
Extracellular matrix proteins 
 20 Collagen 1a1     21.73 ± 2.27 
 31 fibronectin    6.15 ± 1.04 
 54 Laminin B1    2.51 ± 0.35 
 87 SPARC   3.72 ± 0.11 
 94 Tenascin C   1.87 ± 0.20 
 96 vitronectin   1.94 ± 0.68 
Proteases 
 1 Adamts 1     4.19 ± 0.46 
 25 Cathepsin D       1.92 ± 0.36 
 57 Hyaluronidase      2.31 ± 0.58 
 60 MMP12       5.91 ± 1.20 
 67 MMP2    4.15 ± 1.77 
 79 uPA      3.03 ± 0.58 
Protease inhibitor 
 92 Timp1        6.43 ± 1.78 
 93 Timp2        4.71 ± 1.39 
 
 
The listed genes displayed on average a more than 1.8-fold difference between the sham-operated 
and the infarcted animals 2 days after the intervention. The expression levels are shown as -fold 
increase compared to sham operated samples after normalization using the internal control (GAPDH). 
Values represent mean ± SEM of independent hybridizations of RNA isolated from 6 animals for each 
treatment for each time point 
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3.2.2. SPARC protein levels strongly, but transiently increase during 
myocardial remodelling  
 
Having identified SPARC as a gene up-regulated in response to MI, we next wanted to 
test whether the induction of SPARC at the mRNA level also reflected an increase in 
expression of SPARC protein. Because the correlation between mRNA and protein 
expression for a particular gene is highly variable, proteins are the actual effectors of 
most cellular processes, mRNA changes not accompanied by corresponding alterations 
in protein levels may not be mechanistically meaningful. The biological activity of many 
proteins is regulated by sub-cellular localization and post translational modifications, 
neither of which is addressed by transcriptional analysis. To our knowledge, there are 
no investigations of SPARC protein levels following MI in the mouse. We analyzed the 
expression of a 43 kDa glycosylated form of SPARC by Western blot at the time points 
2 days, 7 days, 1 month, and 2 months after MI. In line with the observed changes in 
mRNA levels, SPARC protein levels were strongly increased upon myocardial infarction 
with a maximal induction at day 7. Within the next 2 months, SPARC protein levels 
returned to the background levels of sham-operated animals. Probing of the 
membranes with antibodies against GAPDH demonstrated equal loading of the 
samples. Quantification of the Western Blot signals indicated a significant increase in 
SPARC protein expression at day 2 (2.58±0.21 fold, p<0.01, n=12), day 7 (3.72±0.28 
fold, p<0.01, n=12) and 1 month (1.9±0.16 fold, p<0.01, n=12) following the infarction, 
respectively (Fig.3.2). Furthermore, the kinetic of SPARC expression indicates that this 
protein presumably plays a transient role during the remodeling of the infarcted heart 
tissue.  
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ig 3.2 Changes in SPARC protein levels following myocardial infarction. 
Western Blot of sham-operated mice (Ctr) or infarcted animals (MI) at the indicated 
times after the procedure (upper panel). Each lane was loaded with 15µg protein of 
the tissue extract. for GAPDH. The bar diagraph indicates the quantification of 
SPARC expression Following Semi-quantitative analysis of SPARC in mouse hearts 
at different times after MI as indicated. Data are expressed as fold changes from 
corresponding sham-operated mice after normalization.  Values are mean ± SEM; 
n=12 *P< 0.01 vs. corresponding sham –operated animals; # P < 0.05 vs. MI-7d. One 
way ANOVA test. 
 
 
3.2.3. Enhanced SPARC expression occurs predominantly in the infarcted area  
 
To analyze the tissue distribution of SPARC after myocardial infarction, frozen 
sections of infarcted tissue or control mouse hearts were stained with anti-SPARC 
antibodies and detected with fluorescence-labeled secondary antibodies. To identify 
both cardiomyocytes and non-myocytes, cellular actin and nuclei were also labeled 
with phalloidin-rhodamine and DAPI, respectively (Fig. 2). To test for specificity of the 
SPARC antibody used, either the SPARC antibody was omitted (data not shown) or a 
blocking peptide (encompassing the region used to generate the SPARC antibody) 
was included. No significant SPARC staining could be observed in the negative 
controls (“blocking peptide” in Fig. 2). Importantly, the expression of SPARC was low 
in normal heart tissue (Fig. 2). However, 2 days after infarction, significant increases in 
SPARC expression could be observed in the infarcted area. In parallel, a decrease in 
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the phalloidin staining, suggestive of actin degradation in the infarct zone, together 
with an increased number of nuclei, suggestive of invasion of inflammatory cells and 
fibroblasts, could be observed. Moreover, 7 days after the infarction, strong SPARC 
staining was evident with further reduction in the actin signal and a strongly increased 
number of nuclei (presumably non-myocytes). SPARC deposition was localized 
dominantly to the infarcted area surrounding the invaded fibroblasts and inflammatory 
cells. Strikingly, 2 months after the experimental infarction, SPARC immunoreactivity 
in the infarcted area was decreased again to the background levels seen in normal 
heart tissue, while an organized scar tissue without actin staining and elevated nuclear 
signal from fibroblasts and other non-myocytes could be seen. These data 
demonstrated that enhanced expression of SPARC is transient in the remodeling 
tissue. Furthermore, up-regulation of SPARC coincides with the invasion of fibroblasts 
and the induction of scar formation in the injured heart tissue.  
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Figure 3.3  Immunofluorescence studies of mouse frozen myocardial tissue sections 
for SPARC, nuclei and actin after MI. Tissue sections were stained with goat anti-SPARC 
IgG, Alexa 546-Phalloidin (actin), DAPI (nuclei) and, followed by Cy2-anti goat secondary 
antibody. A, the signal of SPARC, the corresponding nuclei and actin staining in the Sham-
operated group, SPARC is diffusely observed in normal myocardium section, the nuclei of 
cells and actin is clearly to be seen. B, after MI-2d immunostaining for SPARC is enhanced 
along the margin of the infarcted area, while the actin signal is reduced. C, after 7 days of 
MI, the SPARC staining is increased at sites of the infarcted area (arrows). DAPI staining 
noted a large number of nuclei in the infarcted area, while the corresponding actin staining 
is hardly  found .D, After 2m of MI the signal of SPARC remains present  in non infarcted 
myocardium but not in the infarcted area as seen after 7d. 
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2.2.4. Induction of SPARC depends on integrin αv function 
 
3.2.4.1.Regulated SPARC gene expression 
 
Previously, we have observed a prominent role of integrins in modulating tissue 
remodeling events upon myocardial infarction.Therefore, mice that underwent 
myocardial infarction were simultaneously treated with a specific integrin αv inhibitor or 
the vehicle control. Gene expression events observed in infarcted animals treated with 
the vehicle control were identical to those observed previously upon myocardial 
infarction and the same set of genes was found to be up regulated after 7 days (Fig. 
3.4). Importantly, upregulation of SPARC expression following myocardial infarction 
was dependent on integrin αv function as the inhibitor blocked the increase in SPARC 
mRNA at day 2 (1.42±0.37 fold) and day 7 (1.64±0.29) after myocardial infarction. 
This was in contrast to the 2.58±0.24 fold and 3.78±0.11 fold induction of SPARC 
mRNA after 2 days and 7 days after infarction in the vehicle control group, 
respectively.  
 
  
  
Fig 3.4 Representative gene expression profile of the effect of integrin αv on ECM 
gene expression. gene expression analysis in mouse myocardium 7 days after 
experimental myocardial infarction and sham-operated detected by cDNA expression 
array system. RNA was extracted from mouse heart after myocardial infarction or sham-
operated. Total 5µg was reverse-transcribed and labelled in labelled with biotin, and gene 
expression was detected using Nonrad- GEArray Q series kit as described in method. 
The intensity of the data by first subtracting the average background (mean blank 
intensity) and then comparing intensity levels with the average intensity of the 
hybridization signal of the house keeping gene,  
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3.2.4.2. Modulation of SPARC protein level 
 
To verify the result from the gene array, the protein level of SPARC was detected by 
Western blots. Again, the upregulation of SPARC protein expression was closely 
followed by similar increases in SPARC mRNA levels. Inhibition of integrin αv severely 
blocked the increase in SPARC protein 2 days (1.58±0.24 fold vs. 2.58±0.21 fold, 
p>0.01, n=12) and 7 days (1.63±0.22 fold vs. 3.72±0.28 fold, p>0.01, n=12) after 
infarction (Fig. 3.5).  
 
  
    
 
Figure 3.5 SPARC protein expression in mouse hearts 2 and 7 days after MI. 
Application of the αv integrin inhibitor via mini-pumps blocked the increase in SPARC 
protein expression. Data are expressed as fold changes from corresponding sham-
operated mice, normalized to GAPDH. Values are mean ± SEM; n= 12; * = p< 0.01 ctr vs. 
sham operated animals; # = p < 0.05 MI vs. MI-Inh.  
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3.3. Discussion 
 
Expression and abundance of extracellular matrix proteins and their cellular receptors 
undergoes dramatic changes following myocardial infarction to keep up organ function. 
In the present study, we analyzed gene expression changes upon experimental 
myocardial infarction in the mouse and followed these changes in the course of the 
healing response up to 1 month after infarction. Most strikingly, we observed a transient 
and locally confined increase in SPARC expression in response to myocardial 
infarction. Induction of SPARC depended in part, on v integrin function and localized to 
the infarcted heart tissue undergoing active remodeling. our results pointed to an 
important role of SPARC in the transient healing response after myocardial infarction. 
Several studies have indicated that SPARC expression is high during embryonic 
development, but usually low during normal postnatal life. However, SPARC can be 
induced in various tissues such as bone, gut mucosa and skin during healing responses 
(Holland, Harper et al. 1987; Sage, Decker et al. 1989) and enhanced SPARC 
expression is associated with malignant tumors (Porter, Sage et al. 1995). In these 
contexts, SPARC may contribute to the reorganization of connective tissue and 
stimulate angiogenesis (Sage, Vernon et al. 1989; Reed, Puolakkainen et al. 1993). 
With respect to heart tissue, SPARC is abundantly expressed in this organ during early 
development. In contrast, its expression in the heart is very low during adulthood 
(Holland, Harper et al. 1987; Sage, Vernon et al. 1989). Importantly, increased mRNA 
levels of SPARC have been detected in the myocardium following myocardial 
infarction.(Stanton, Garrard et al. 2000; Komatsubara, Murakami et al. 2003) indicating 
a role for SPARC in matrix remodeling during wound healing in the heart.  
One of the important properties of SPARC is its anti-adhesive effect. Accordingly, 
SPARC can modulate the interactions between cells and their surrounding matrix by 
inhibiting adhesion and spreading on a collagen matrix (Sage and Bornstein 1991). In 
the process of repair after myocardial infarction, necrotic cells in the infarcted area are 
gradually resorbed and being replaced by scar tissue. Scar formation is already evident 
within a few days after infarction and the scar tissue is characterized mainly by a 
collagen- and fibronectin-rich extracellular matrix and the presence of fibroblasts. Our 
gene expression analysis demonstrates that SPARC is co-regulated together with 
several extracellular matrix proteins including collagen, fibronectin, and laminin and their 
enhanced transcription is detectable within 2 days after infarction. By immunostaining, 
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the increased SPARC protein levels were localized to the margin of the infarcted, 
necrotic tissue during the initial healing response. These results indicate that during the 
acute phase after myocardial infarction, cardiomyocytes and interstitial fibroblasts in the 
border zone between intact and damaged heart tissue synthesize SPARC. This early 
increase in SPARC might help to loosen the strong adhesive connections between 
surviving cardiomyocytes and connective tissue, thereby allowing the influx of 
fibroblasts, facilitating tissue reorganization and scar formation. 
Direct SPARC induction through integrin αv subunit has been reported in human 
melanoma cells. However, the molecular mechanism that connects myocardial 
infarction with increased SPARC expression in vivo is currently unknown. Our results 
established an important role for integrin αv in the regulation of SPARC in vivo, as 
SPARC mRNA levels were severely compromised in infarcted animals receiving a 
specific integrin αv inhibitor.  
Together, our data suggest an important role for the matricellular protein SPARC in 
the healing response following myocardial infarction. Deposition of SPARC in the 
infarcted zone seems to be intimately involved in scar formation. Additionally, we 
suggest that SPARC has an impact not only in the direct scar area, but also in the 
remote regions with regard to collagen incorporation. 
Whether the transient up-regulation of SPARC after myocardial infarction is essential for 
the maintenance of cardiac structure and function requires further investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chapter 4 
 
Fibroblast migration is modulated by SPARC 
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4. Fibroblast migration is modulated by SPARC  
 
Migration is an important process involved in development, wound healing and 
angiogenesis. During migration cells are required to spatially coordinate 
polarization, adhesion to the substratum, and actin polymerization to move the 
membrane in the direction of migration. 
 
 
     (Edin, Howe et al. 2001)  
  
 
 
4.1 Introduction  
 
SPARC (secreted protein, acidic and rich in cysteine) is a 43 KD matricelluar protein 
which is also known as BM-40 or osteonectin. The best- characterized matricellular 
proteins include the tenascins, thrombospondin-1 and -2 and SPARC. These proteins 
are secreted by numerous cell types and have multiple functions. SPARC is a 
secreted Ca2+-binding glycoprotein, which can interact with several extracellular 
matrix molecules and cytokines.(Sun and Weber 2000). The protein was first purified 
as a major non-collagenous component of bovine bone, with binding affinity to 
collagenI-I(Termine, Kleinman et al. 1981; Murphy-Ullrich 2001; Wang, Fertala et al. 
2005) SPARC is expressed at high levels in many different tissues and cell types in 
both embryonic and adult mice The precise functions of SPARC are unclear, but it 
appears to counter cellular adhesion when it is in solution or incorporated into a 
substrate (Murphy-Ullrich 2001). SPARC is believed to exert its anti-adhesive effects 
on many cell types, resulting in cell rounding and partial detachment from the cell 
substrate. Furthermore, SPARC is expressed by tissues undergoing morphogenesis 
and modulates the attachment and spreading of various cell types on extracellular 
matrixes (Paulsson, Deutzmann et al. 1986; Sage and Bornstein 1991). Recently, 
upregulation of gene expression in injured heart was reported (Stanton, Garrard et al. 
2000). Importantly, a transient increase of SPARC protein levels after myocardial 
infarction was observed in our study. SPARC could be secreted by a several cell type 
present in the mouse heart, such as fibroblasts, endothelial cells or macrophages, 
but the precise cellular origin of SPARC during the remodeling of the injured heart is 
still speculative. 
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SPARC is known to bind to certain growth factors. SPARC could modulate 
PDGF activity during inflammation and tissue repair by limiting the availability of 
dimers containing the PDGF–B subunit (Raines, Lane et al. 1992). Transforming 
growth factor beta1 (TGF-β1) is well known as a cytokine involved in wound healing 
and it is also found to be up-regulated after MI mediating tissue repair (Thompson, 
Bazoberry et al. 1988). TGF-β1 is a distinct TGF-β isoform which is capable  to 
stimulate the production of ECM components in a variety of cell types. TGF-β1 and 
SPARC have been reported to be associated with the rapid remodeling of connective 
tissue that occurs in wound healing and developmental processes (Wrana, Overall et 
al. 1991). SPARC and TGF-β1 can engage one another in a reciprocal relationship, 
previous studies have shown that TGF-β1 increases SPARC expression at mRNA 
and protein levels in fibroblasts and osteoblasts, whereas, SPARC induces TGF-β1 
expression in Mv1Lu and R1B cells (Wrana, Overall et al. 1991). These data suggest 
that the link between SPAR and growth factors like TGF-β1 and PDGF-BB play a role 
in wound healing. 
SPARC protein induction through β3 integrin expression has been reported 
(Sturm, Satyamoorthy et al. 2002). SPARC is able to promote tumor cell migration 
and this activity of SPARC is functionally connected to integrins αvβ3 and αvβ5 on 
cancer cells (De, Chen et al. 2003). These findings suggest that tissue remodeling 
processes during tumor growth or wound repair are influenced by an interplay 
between integrins, including αv containing receptors, and the matricellular protein 
SPARC. Recent studies have also indicated an increased expression of SPARC in 
the myocardium after injury or stress 
Adequate wound healing and scar formation is an essential response to 
myocardial infarction (MI). Following myocardial infarction, dead tissue is necrosed 
and replaced by a scar composed primarily of type 1 collagen. Fibroblasts are 
primary cellular components regulating the process. Myofibroblasts (MyoFb) first 
appeared at these sites of repair on day 3 and remained abundant thereafter at all 
time points examined; Fibroblast migration to infracted area and proliferation is 
critical to the scar formation. The process of wound healing after myocardial 
infarction begins with clearance of necrotic myocytes and other cell debris and is 
closely followed by migration of myofibroblasts into the infarct zone where these cells 
proliferate synthesize new extracelluar matrix proteins. and mediate wound 
contraction to form the mature scar.Our study in chapter 3 results suggest that 
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SPARC, as expressed in post-MI heart, predominately in the scar area may play an 
important role in ongoing remodeling of the scar. SPARC’s properties to interact with 
extracellular matrix and to promote de-adhesion of cells from the matrix, contribute to 
a cellular state conducive to migration.  
In this study, we further investigated the expression and regulation of SPARC 
in isolated cell types in vitro and followed the hypothesis that SPARC expression 
might be induced by integrins and increased SPARC levels may account for scar 
formation after myocardial infarction via fibroblasts invasion.   
 
4.2. Results  
 
4.2.1. Induction of SPARC by TGF-β1 and PDGF in fibroblasts and 
cardiomyocytes  
 
The local distribution of SPARC in the infarcted heart could result from its expression 
by either cardiomyocytes or invading fibroblasts. To investigate the cellular origin of 
SPARC and the role of integrin αv in this process, we compared SPARC secretion by 
isolated mouse fibroblasts and neonatal rat cardiomyocytes. Cardiomyocytes were 
isolated as described in Material and Methods and stained for the cardiomyocyte-
specific protein troponin. Cultures of primary cells contained more than 95% of 
troponin-positive cells (Figure 4.1). To analyse SPARC expression by different cell 
types, fibroblasts and isolated neonatal rat cardiomyocytes were preincubated in 
serum-deprived medium for 12 h and then incubated for 72h with TGF-β1or PDGF in 
the serum-free medium. Due to the limited viability of cells in serum-free medium, we 
could maintain cardimyocytes and fibroblasts under the serum-starved condition for 
only a maximum of 72 h. Faint levels of accumulated SPARC protein after 36 –h 
incubation under non-stimulus conditions were detected. However, there are no 
significant different between the TGF-β1 stimulated cells and untreated cells. (data is 
not shown) This weak protein expression may indicate that SPARC was able to be 
slowly released from the intracellular pool after serum-starvation (Gooden, M.D. et 
al., ).SPARC protein in the culture medium was detected by western blots (Figure 
4.2). By using an anti-SPARC antibody, obvious immuno-staining for SPARC was 
observed in myocardial cells of rat neonatal cardiac tissue (Figure 4.1). In both 
cases, basal SPARC secretion in serum-free medium was low, but could be strongly 
induced upon treatment of the cells with either platelet-derived growth factor (PDGF-
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BB) or TGF-β1. Interestingly, plating of fibroblasts or cardiomyocytes onto vitronectin, 
a well characterized ligand for integrin αv, had no effect on SPARC expression in 
cardiomyocytes or fibroblasts However, SPARC expression in isolated cardiac 
myocytes could be strongly stimulated by TGF-ß1 (2.8±0.1fold, p<0.01) and PDGF 
(2.3±0.3 fold, p<0.01)(Fig. 4.2A). Similarly, treatment of fibroblasts with either TGF-
ß1 (3.9±0.26 fold, p<0.01) or PDGF (3.2±0.30 fold, p<0.01) significantly increased 
SPARC expression as compared to untreated cells (ctr) (Fig. 4.2 B). Consistent with 
the failure of VN to stimulate SPARC expression, inhibition of integrin αv did not 
interfere with TGF-β1 or PDGF stimulated SPARC secretion as determined by ELISA 
assays (Fig 4.3.A and 4.3.B). SPARC secretion by fibroblasts in response to TGF-β1 
or PDGF was considerably higher (TGF-β1: 855ng/ml±46; PDGF: 721ng/ml±44) than 
the levels of SPARC secreted by cardiac myocytes (TGF-β1: 220ng/ml±33; PDGF: 
189ng/ml±25) (Fig. 4.3 A and 4.3 B). These results suggested that the effect of 
integrin αv on SPARC expression in vivo might be indirect and integrin αv might 
function upstream from growth factor mediated stimulation of SPARC expression. 
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Troponin-I staining for cardiomyocytes     
  
 
 
Figure 4.1. .Induction of SPARC expression in neonatal rat cardiomyocytes. 
Cardiomyocytes were isolated from neonatal rats, cultured and serum starved cells were 
treated by adding TGF-ß 1 (5µg/ml) or PDGF-BB (5µg/ml) for 72 hours before fixation. 
Immunofluorescence was performed with anti-SPARC, anti-troponin-I and DAPI as 
indicared. Cardiomyocytes were identified by troponin-I staining which is only expressed 
in cardiomyocyte. SPARC expression in untreated cardiomyocytes is predominantely 
perinuclear. After Growth factor stimulation there was a clear increase in SPARC 
immunoreactivity in the cytosol of cardiomyocytes. All figure s are of the same 
magnification. Scale bar =50um as indicated,  
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Figure 4.2 SPARC expression in cardiac myocytes and fibroblasts. Cultured cardiac 
myocytes (A) or fibroblasts (B) were stimulated with TGF-ß1 (5ng/ml) PDGF-BB (5ng/ml) 
or vitronectin (1µg/ml) respectively. Expression of SPARC was analysed by Western 
blotting of conditional medium from cultured rat neonatal myocardial cells with a anti-
SPARC antibody (upper panel). Culture medium from equal amounts of cells (2x10 5) 
was loaded in each lane. In parallel, GAPDH was detected in the same samples with a 
monoclonal/polyclonal antibody (middle panel). Bar graphs depict mean values of the fold 
induction of SPARC expression in cardiomyocytes (A) or fibroblasts (B) ± sem compiled 
from three separate experiments. * p<0.05 vs untreated myocardiocytes or fibroblasts, 
respectively. 
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Figure 4.3 SPARC secretion by neonatal rat cardiac myocytes and mouse fibroblasts as 
measured by enzyme-linked immunosorbent assay. Cardiac myocytes (A) or fibroblasts 
(B) were treated by TGF-ß1 (5ng/ml) or PDGF-BB (5ng/ml) with or without integrin αv inhibitor 
(10mM) for 72 hours. SPARC secretion (ng/106 cells) was determined in conditioned culture 
medium using the SPARC ELISA kit according to the manufacturer’s protocol. Bars represent 
the concentration of SPARC in different samples. Values are the mean ± SEM, *p<0.05 vs. 
untreated cells (n=12).. 
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4.2.2. Vitronectin stimulates TGF-β1 and PDGF expression in cardiac myocytes 
 
To investigate if integrin αv engagement might indirectly impact on SPARC gene 
expression by modulating the secretion of growth factors, we studied TGF-β1 and 
PDGF-BB expression in cardiac myocytes after stimulation with vitronectin. 
Vitronectin is a major ligand for the vitronectin receptors integrins αVβ3 or αVβ5. We 
observed that incubation of isolated cardiac myocytes with vitronectin (1µg/ml) 
significantly increased the secretion of TGF-β1 (423 ±115 pg/ml; n=12, p<0.05) as 
well as PDGF (84±17pg/ml; n=12, p<0.05) as compared to untreated cells (Fig.4.4 A 
and B). This increase was completely abrogated by addition of an integrin αv inhibitor. 
Interestingly, no significant stimulation of TGF-β1 and PDGF expression by 
vitronectin was observed in fibroblasts (figure 4.5).  
Together, the data obtained with isolated cells suggested that in vivo a cross-
talk between different cell types might finally lead to SPARC secretion and that the 
initial VN-induced and integrin αv-mediated growth factor release from cardiac 
myocytes might promote strong SPARC expression predominantly by fibroblasts 
(Figure 4.6) 
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Figure 4.4 Induction of growth factors by vitronectin in neonatal rat cardiac 
myocytes. Vitronetin treated of cardiac myocytes increase A) TGF-β1and B) PDGF-BB 
protein levels in cardiac myocytes. The increase was abrogated by addition of Integrin 
αv inhibitor. Serum staved neonatal cardiac myocytes were treated by either vitronectin 
(1ug/ml) or PBS (ctr) with or without integrin αv inhibitor (10mM) for 72 hours. TGF-β1 
and PDGF-BB content (pg/106 cells) was derermined in conditioned medium using the 
TGF-β1 and PDGF-BB ELISA kit respectively  according to the manufacturer’s 
protocol. Bars represent the concentration of SPARC in different groups. Each 
treatment was performed in triplicate. Cell numbers were determined and protein 
values were normalized to cell number. Values are the mean ± SEM, *P<0.05 vs. 
untreated cardiac myocytes (n=12). 
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Figure 4.5 Induction of growth factors by vitronectin in fibroblasts. Serum staved 
neonatal cardiac myocytes were treated by either vitronectin (1ug/ml) or PBS (ctr) with or 
without integrin αv inhibitor (10mM) for 72 hours. TGF-β1 and PDGF-BB content (pg/106 
cells) was derermined in conditioned medium using the TGF-β1 and PDGF-BB ELISA kit 
respectively  according to the manufacturer’s protocol. Bars represent the concentration of 
growth factorsin different groups. A) Treatment fibroblasts with either vitronetin or integrin 
αv inhibitor did not impact on TGFβ1 expression as indicated in the figure. B) PDGF-BB 
protein levels in fibroblast were not influenced by treatment of either vitronectin or inhibitor 
alone. But there is a induction of PDGF-BB by treatment of combinations of vitronectin and 
integrin αv.. Each treatment was performed in triplicate. Cell numbers were determined and 
protein values were normalized to cell number. Values are the mean ± SEM, *P<0.05 vs 
untreated fibroblasts. 
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figure 4.6 Schematic drawing of induction of SPARC expression. Treatment with 
vitronectin increases the expression of growth factors (TGF-β1 and PDGF-BB) by 
cardiac myocytes. Secreted growth factors promote strong SPARC expression 
predominantly by fibroblasts. Induction of SPARC expression by the growth factors 
could not be interfered by integrin αv inhibitor directly in the same cells, but expression 
of the growth factors itself by cardiac myocytes could be abrogated by addition of 
integrin αv inhibitor .Symbols present cardiac myocyte and fibroblast are indicated.   
 
 
 
 
4.2.3. Behavior of SPARC in FN inducted migration of fibroblasts  
 
4.2.3.1.SPARC modulates the haptotaxis response of fibroblasts towards fibronectin 
 
The experiments described in chapter 2 and chapter 3 demonstrated a transient up-
regulation of SPARC during the remodeling of the injured mouse heart in vivo. 
Furthermore, increased ECM gene expression after aortic banding or myocardial 
infarction was observed in our study. Fibronectin (FN) is involved in many cellular 
processes, including tissue repair, embryogenesis, blood clotting, and cell 
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migration/adhesion. Fibronectin sometimes serves as a general cell adhesion 
molecule by anchoring cells to collagen or proteoglycan substrates. FN also can 
serve to organize cellular interaction with the ECM by binding to different 
components of the extracellular matrix and to membrane-bound FN receptors on cell 
surfaces(Farhadian, Contard et al. 1995).To get an idea about the functional 
significance of SPARC during wound healing, we analyzed the haptotaxis response 
of fibroblasts on a fibronectin (FN) matrix in the presence or absence of SPARC. 
Haptotaxis is the directed movement of cells induced by a gradient of an immobilized 
stimulus such afrom chemotaxis that is induced by soluble stimuli. 
To this end, modified Boyden migration chambers were coated on the underside of 
the membrane with different combinations of FN and SPARC and fibroblasts seeded 
into the top compartment were allowed to migrate for 7 h. Clearly, FN-coated 
chambers stimulated a dose-dependent migratory response, whereas in control 
chambers, where the membrane had been coated with BSA, fibroblasts did not 
migrate from the top to the bottom compartment (Fig.4.7). Interestingly, coating with 
a combination of FN and a constant amount of SPARC (1 µg/ml) led to an increased 
haptotaxis response for each FN concentration tested as compared to the response 
towards FN alone. In an attempt to specifically abrogate the effect of SPARC, a 
SPARC antibody was used, whose specificity was demonstrated in previous 
experiments (chapter 3). The effect of SPARC could be blocked by adding a 
polyclonal anti-SPARC antibody (Santa Cruz) at 1ug/100ml (anti SPARC 100 ul and 
SPARC 1µg incubated at RT for half an hour) demonstrating the specificity of 
SPARC-mediated enhancement of FN-stimulated migration. 
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Figure 4.7 Effect of SPARC on FN-induced fibroblasts migration. The migration behaviour 
was assessed in haptotaxis assays using modified Boyden migration chambers coated with 
fibronectin (FN) at the indicated concentrations in the absence (open bar) or the presence of 
SPARC (1µg/ml; closed bar) and the combination (FN and SPARC) with a specific SPARC 
antibody for two hours (gray bars) The results are expressed as numbers of migrated cells in 
8-10 random fields/chamber at 20x power. Serum starved fibroblasts were employed in the 
migration chambers. After migration 7 h, cells on the lower side of the membrane were fixed, 
stained, and counted. ‘’0’’, ‘’1’’, ‘’5’’,’’10’’ were the respective concentration of FN (µg/ml) as 
indicated in the figure, diluted in EMDM media only. No migration was observed when 
absence of FN. There is an elevated fibroblasts migration with rising fibrometin concentration. 
The combination of FN and SPARC further promotes the migration with a significant difference 
as compared to that FN used alone Addition of an anti-SPARC antibody abolishes effects of 
SPARC on FN-induced cell migration.  Bars represent means ± S.D. from three independent 
experiments.  Error bars represent the standard error of the mean. *P<0.05 vs absent SPARC 
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4.2.3.2. Effect of SPARC on haptotaxis response of fibroblast is concentration 
dependent 
 
The effect of SPARC on FN –stimulated cell migration have been studied previously 
in other cell types. However, whereas in some cases a negative effect of SPARC on 
cell migration has been observed (hagan, S 2003), other results have found a 
supporting role of SPARC on cell migration. These contrasting results might be due 
to the use of different concentrations of SPARC, as dependent on the concentration 
SPARC exerted either a promotive or a counteracting effect on cell migration. 
Interestingly, SPARC on its own at concentrations ranging from 1 to10 µg/ml did not 
influence cell motility (Fig.4.8). Again, a combination of fibronectin (1 µg/ml) and low 
concentrations of SPARC (1 µg/ml) enhanced FN-stimulated fibroblast migration. In 
contrast, when higher SPARC concentrations (5 – 10 µg/ml) were combined with a 
given concentration of fibronectin (1 µg/ml), the promigratory activity of SPARC was 
reversed and an inhibitory effect of SPARC was observed This inhibitory effect of 
SPARC at higher concentrations could be overcome by addition of 0.5% FBS 
demonstrating that the used commercial preparation of SPARC was not 
contaminated by general inhibitors of cell migration (Fig 4.8).  
To further provide evidence for the purity of the used SPARC preparation we 
separated the commercial SPARC preparation by SDS-PAGE and performed silver 
staining of the resulting gel (Figure 4.9). Whereas low concentrations from 1 µg of 
SPARC could be easily observed, no additional protein bands in the size range from 
10 – 80 kDa could be detected. In addition, 500 ng or 1 µg of the growth factors TGF 
and PDGF, respectively, were readily detected by the silver staining. From this 
experiment we conclude that the SPARC preparation we used was not only devoid of 
TGF and PDGF but also devoid of other protein contaminations.   
Finely, our results provide evidence that SPARC can modulate ECM-triggered 
haptotaxis of fibroblasts. Furthermore, these data are in line with the idea that 
SPARC acts as a switch to first promote and then at higher concentrations to shut off 
fibroblast migration during tissue remodeling events. (Figure 4.11) 
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Figure,  4.8 Concentration dependent effect of SPARC on Haptotaxis of fibroblasts.  The 
haptotaxis was analysed in Boyden chambers coated with SPARC at the indicated 
concentrations in the absence or the presence of FN (1µg/ml) Results are expressed as 
counted migrated cells in 8-10 random fields/chamber at 20x power. Serum starved fibroblasts 
were employed in the migration chambers. After migration 7 h, cells on the lower side of the 
membrane were fixed, stained, and counted. ‘’0’’, ‘’1’’, ‘’5’’,’’10’’ were the respective 
concentration of SPARC (µg/ml) as indicated in the figure, diluted in EMDM media only. No 
migration was observed when SPARC at concentrations ranging from 1 to10 
µg/ml used alone. Whereas low concentrations of SPARC enhance FN-initiated 
haptotaxis, higher SPARC concentrations have an inhibitory effect. Addition of FBS (0.5%) 
overcomes the inhibitory effect of high amounts of SPARC, demonstrating that purified 
SPARC is not contaminated with general inhibitors of migration. Bars represent means ± S.D. 
from three independent experiments.  Error bars represent the standard error of the mean 
*P<0.05 vs absent of SPARC   
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Figure 4.9 representative fields of view from migration. Millicell modified Boyden 
chambers  were employed in haptotaxis assays, the lower surface of the Millicell 
polycarbonate membrane was coated on the underside of the membrane with 0.1% 
BSA, 1µg FN and different combinations of FN and SPARC  respectively. SPARC 
increased FN-stimulated fibroblast migration at a low concentration (1µg/ml). the 
migration towards a source of combination of FN and SPARC was diminished at a high 
level of SPARC (10µg/ml)   
 
 
 
  
 
 
Figure 4.10 SPARC Silver staining of a SDS gradient gel (4-12%). Different amounts 
of the commercial SPARC preparation were separated by SDS-PAGE. 500 ng TGF and 1 
µg PDGF (in 0.5% BSA solution) were used as growth factor standards. After silver 
staining low concentrations of SPARC (1 µg) or of the growth factors (500 ng) could be 
easily detected. No contamination of the SPARC preparation with additional proteins was 
observed. 
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Figure.4.11. Schematic drawing summarizing wound healing processes after 
myocardial infarction (MI) with special regard to SPARC expression and 
fibroblast migration. A) As a result of myocardial  ischemia there is an increased 
expression of growth factors (e.g. TGF and PDGF), These growth factors mainly act on 
fibroblasts. B) SPARC expression from fibroblasts may open up spaces for the invading 
fibroblasts (activated by TGF/PDGF) and simultaneously act as haptotactic stimulus to 
promote further fibroblast migration. C) Fibroblasts eventually cause wound healing and 
scar formation after myocardial infarction with deposition of collagen. In our model, 
especially SPARC causes fibroblast migration to the resulting scar area.  
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4.3. Discussion  
 
The molecular mechanism that connects myocardial infarction with increased 
SPARC expression in vivo is currently unknown. To this point, our results clearly 
establish an important role for integrin αv in the regulation of SPARC in vivo, as 
SPARC mRNA levels were severely compromised in infarcted animals receiving a 
specific integrin αv inhibitor.  
However, stimulation of isolated cardiac myocytes or fibroblasts with vitronectin, a 
well characterized ligand for integrins αvß3 and αvß5, failed to induce SPARC 
secretion in vitro suggesting that integrin αv has an indirect role in the upregulation of 
this matricellular protein. Our further experiments point to growth factors such as 
TGF-β1 and PDGF that moderately induce SPARC secretion in isolated rat neonatal 
cardiac myocytes, but very strongly in fibroblasts. In addition, these growth factors 
have been shown to increase SPARC expression in human gingival fibroblasts, 
rabbit articular chondrocytes, and human pulp cells (Wrana, Overall et al. 1991; 
Zhou, Hammonds et al. 1993; Reed, Vernon et al. 1994; Shiba, Fujita et al. 1998). 
Although growth factor cDNAs were not included on the GEArray and therefore, their 
regulation was not examined after myocardial infarction in the present study, the level 
of TGF-β1 is strongly enhanced in infarcted compared to non-infarcted myocardium 
within 2 days after coronary artery ligation in the rat (Thompson, Bazoberry et al. 
1988; Deten, Holzl et al. 2001). The measurement of TGF, PDGF and SPARC 
secreted from isolated cells in vitro suggests a coordinated sequence of events, 
where in a first step integrin αv engagement on cardiac myocytes causes an 
upregulation of TGF and PDGF. Inhibition of integrin αv can abrogate this vitronectin-
mediated increase in growth factor secretion. In a second step, we envision that 
SPARC expression is increased moderately after TGF and PDGF stimulation of 
cardiac myocytes in an autocrine manner. At the same time, the growth factors 
secreted by cardiac myocytes promote a strong increase in SPARC expression by 
fibroblasts. Such a two step process that requires communication between different 
cell types would also help to explain, why specific integrin αv inhibition, though 
severely interfering with SPARC expression in vivo, did not block growth factor 
induced SPARC expression in vitro. Furthermore, it is also key to understand the 
failure of vitronectin to directly stimulate a significant level of SPARC expression by 
isolated cardiac myocytes or fibroblasts. 
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Together, these observations indicate a complex interplay between growth factors, 
integrins and the induction of ECM and matricellular proteins that mediate the healing 
response in the infarcted heart. Recent work has also demonstrated, that SPARC 
itself can upregulate TGF-ß1 and this upregulation accounts for the secretion of 
collagen I in different cell types(Schiemann, Neil et al. 2003; Francki, McClure et al. 
2004). Most importantly, to understand how SPARC exerts its counteradhesive effect 
in MI remodeling, the modulation of SPARC in fibroblast was investigated. Our 
results provide novel insight into the functional role of SPARC in cell migration 
induced by immobilized ECM proteins. Clearly, SPARC alone did not serve as a 
haptotactic stimulus for fibroblasts. However, in combination with fibronectin, low 
concentrations of SPARC (1 µg/ml) consistently elevated the pro-migratory effect of 
fibronectin. These results are in line with previous reports that have indicated a 
positive effect of SPARC on fibronectin-induced cell migration (Rempel, Golembieski 
et al. 2001) Surprisingly, increases in SPARC concentration in the context of 
constant amounts of fibronectin resulted in an impairment of fibronectin-stimulated 
haptotaxis. These data suggest that the balance between SPARC and fibronectin 
determines the effect of these proteins on cell migration. Indeed, cell migration on 
extracellular matrix substrates requires an optimum balance between adhesion and 
detachment to allow efficient movement of adherent cells. The coexistent effects of 
SPARC on promotion and inhibition of migration has been also observed in a glioma 
cell line (Rempel, Golembieski et al. 2001). As SPARC modulates cellular adhesion 
to the ECM by direct interaction with several ECM proteins (Brekken and Sage 
2000), the concentration of SPARC and more importantly the ratio between SPARC 
and its binding partners in the ECM might influence fibroblast migration in a positive 
or negative way. It is interesting to speculate in this context, that the transient 
accumulation of SPARC in the infarct zone might initially contribute to enhanced 
fibroblast migration into this area, whereas later, with higher SPARC concentrations, 
further fibroblast migration will be diminished. Clearly, studies with SPARC-deficient 
mice have demonstrated that this protein is required for a proper wound healing 
response and efficient cell migration in skin (Basu, Kligman et al. 2001) and this is 
consistent with our findings in the mouse heart after experimental myocardial 
infarction. 
Together, our combined in vivo and in vitro data suggest an important modulatory 
role for the matricellular protein SPARC in the healing response following myocardial 
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infarction. Deposition of SPARC in the infarcted zone seems to be intimately involved 
in scar formation presumably by promoting the migration of fibroblasts. Whether the 
transient up-regulation of SPARC after myocardial infarction is essential for the 
maintenance of cardiac structure and function requires further investigation. 
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5. Materials 
 
5.1. Animals 
 
Wild type adult male and female C57/black mice (Charles River, Sulzfeld, Germany, 
weighing 22-25 g., at the beginning of the study) ; Pregnant rats were from Charles 
River, Sulzfeld, Germany; Adult ß1 knockout mice were obtained from Dr. R. Fässler 
(Max-Planck-Institute of Biochemistry, Martinsried, Germany). Cre-knock out mice 
with a myosin light chain 2v driven promotor for cardiac specificity were obtained 
from Dr. Ken Chien (University of San Diego, CA, USA). All the animals were closely 
monitored for clinical signs of heart failure until echocardiographic, hemodynamic, 
and molecular analyses, which were performed 2days, 7 days, and one month after 
MI. All procedures were approved by the institutional animal research committee and 
kept under conventional conditions in the animal facilities in ‘Medizinische 
Universitätsklinik’ University of Würzburg. Experimental were performed in according 
to the animal care guidelines of the American Physiological Society. 
 
 5.2. Cells: 
Mouse fibroblasts  
Neonatal rat cardiac myocytes  
 
 5.3. Antibodies 
  
Primary antibldy Application Size 
(kDa) 
Dilution Ig Company 
Biotinylated- 
SPARC 
WB 42  1:500 Steptavidin-
peroxidase  
B&D System 
Inc. MN ,U.S.A. 
BAF 941 
SPARC Immuno  1:100 Goat 
polyclonal 
Santa-Cruz- 
Biotechnology,Inc., 
Santa Cruz, U.S.A. 
Sc-13326 
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Troponin I Immuno  1:500 Rabbit 
polyclonal 
Santa-Cruz- 
Biotechnology,Inc., 
Santa Cruz, U:S.A. 
Sc-15368 
Integrin αV WB 25 and 27 1:500 Rabbit 
polyclonal 
Chemicon Inernational, 
Inc., Temecula, U.S.A. 
AB1930 
Integrin β1 WB 130/140  !:1000 Armenian 
hamster 
monoclonal I 
Santa-Cruz- 
Biotechnology,Inc., 
Santa Cruz, U:S.A. 
Timp2 WB 24 1:1000 Mouse anti-
human 
Chemicon Inernational, 
Inc., Temecula, U.S.A. 
MAB3310 
GAPDH WB 37 1:4000 Anti-mouse Chemicon Inernational, 
Inc., Temecula, U.S.A. 
MAB 374 
 
 
5.4.  Proteins 
 
SPARC  (CALBIOCHEM, Merck, Schwalbach, Germany); 
TGF  (Sigma , ST.Louis. Missouri. USA) 
PDGF  (Sigma , ST.Louis. Missouri. USA) 
FN   (Sigma , ST.Louis. Missouri. USA) 
 
5.5. Primer 
 
Cre 5:   5’-TTC GGA TCA GCT ACA CC-3’ 
Cre 3:   5’-AGG TGC CCT TCC CTC TAG A-3’ 
T 56:  5’-AGG TGC CCT TCC CTC TAG A-3’ 
L1:  5’-GTG AAG TAG GTG AAA GGT AAC-3’ 
L26:  5’-TAA AAA GAC AGA ATA AAA CGC AC-3’     
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5.6. Solution and buffer 
5.6.1. Cardiomyocyte preparation 
  
CBFHH ( Calcium and bicarbonat-free Hanks with Hepes) 
 8g NaCl 
 0.4g KCl 
 0.2 MgSO4.7H2O 
 1g Dextrose 
 0.06g KH2PO4 
 0.048g Na2HPO4 anhydrogenous 
 4.77g HEPEA 
 H2O to 1L 
 Adjust PH to 7.4 
  
T&D CBFHH 100ml 
 150mg Trypsin 
 1ml DNAse (2mg/ml ub 0.15MNacl) 
  
MEM/5 and 2% CPSR1:  1LMEM 
 5ml BrdU (20 mM stock solution ) 
 1ml Vitamin B12(2mg/ml stock solution) 
 1ml Penicillin (782g dissolved in 25 ml) 
 50 ml Charcoal -stripped FCS (for MEM/5)  
 20 ml CPSR1(for 2% CPSR1 medium) 
  
5.6.2.Fibroblasts cells culture 
  
Starvation medium 100 DMEM 
 0.5% FCS ( Fatal calf serum) 
  
anti trypsinization solution 100 ml DMED 
 0.25 mg BSA 
 Thoy bean trpsin inhibitor 25mg  
  
PBS (1x) 0.2 g KCl 
 0.2 g KH2PO4 
 0.1 g MgCl2H2O 
 8g NaCl 
 2.16 g Na2HPO47H2O 
 pH 7.4 
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5.6.3 For DAN electrophoresis  
  
Agarose gel Agarose Ultrapure 2% 
 1x TAE 
 Ethidum bromide ( 0.5 µg/ml ) 
  
6x loading Dye (Agarose gel) 0.25 % bromphenol blue 
 30 % glycerol in water 
 0.25 % xylen cyanol 
  
TAE ( 50x ) 242 g  Tris base 
 57.1 ml Acetic acid   
 100ml 0.5M EDTA 
 Add  H2O to 1 liter ,adjust pH to 8.5. 
  
5.6.4. RNA 
  
MOPS running buffer (10x) 41.86 g MOPS 
 6.8 g NaOAc.3H2O 
 3.8 g Na4EDTA  
 H2O to 1L 
  
RNA electrophoresis 1 g Agarose 
 88 µml H2O DEPC 
 10 ml 10x MOPS buffer 
 2.3 µl EtBr 
 1.87 ml Formaldehyde  
  
RNA loading dye 720 µl Formamide 
 160 µl 10xMOPS buffer 
 260 µl Formaldehyde 
 193 µl H2O 
 267 µl 6x Bromophenol blue DAN loading dye 
  
5.6.5. cDNA Array 
  
10 x Dnase 1 Buffer 400 mM Tris-HCl (pH 7.5 ) 
 100 mM NaCl 
  60 mM MgCl2 
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20 X SSC 175.3 g NaCl 
 88.2 G Na3Citrate.2H2O 
  
5.6.6. Western blot  
  
2% Tris-Triton Lysis Buffer  2 ml Triton-x 100           
 10 mM EGTA        
 200 µl NaVO3 (1000 x )   
 Tris-HCL (100mM)  
 H2O up to 100  ml 
 Adjust pH to 7,4 
  
PBS ( 10x ) 2 g KCl 
 2 g KH2PO4 
 80 g NaCl 
 11.5 g Na2HPO4 
  
Western Blot Buffer 10x TBST 100 ml 0.5 M EDTA 
 12.1g Tris-Base 
  
Running Buffer 24 g Tris-Base              
 116 g Glycine                
 20 ml 20% SDS 
 4L sterile H2O  
  
RIPA Buffer: 1x PBS 
 1% lgepal CA-630 
 0.5% Sodium deoxycholate 
 4 L sterile  H2O  
  
Transfer Buffer  12g Tris-Base              
 28 g Glycine  
 800 ml Methanol  
 Sterile H2O up to 1 liter  pH 7,5 
 57.1 ml Glacial acetic acid  
  
20% SDS 200 g SDS  
  
PBST 1xPBS with 0.05% Tween 20 
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Stripping Solution 67g Guanidine-HCl (7M) 
 374mg Glycine (50 mM ) 
 1.86mgEDTA ( 0,05 ) 
 740mg KCL (0,1 M ) 
 156mg 2 (beta )-Mercaptoethanol ( 20 mM ) 
 Sterile H2O up to 100 ml 
 adjust pH to 10,8 with 10 M NaOH  
  
SDS  Gels: 
  
Buffer 1,5 M Tris-Base: 
 0,5 M Tris-Base  
 Ammoniu Persulfate ( APS ) 10 % 
 SDS 20% 
 Acrylamide 40% (premade solution ) 
 Bisacrylamide 2% ( premade solution ) 
 
Seperating SDS Gels 
 
Buffers /% 7.5% (ml) 10% (ml) 12.5% (ml) 
H20 16 13.8 10.9 
1.5 M Tris-Base 11.3 11.3 11.3 
20 % SDS 280µl 280 µl 280 µl 
40 % Acryl 10.5 14 17.5 
2 % Bis 4.1 2.7 2.2 
TEMED 14µl 14 µl 14 µl 
APS 10% 315 µl 315 µl 315 µl 
 
4 % Stacking gels:   
 
H2O 9 ml  
0.5 M Tris 1.75 ml 
20% SDS 90 µl 
40% Acryl 1.8 ml 
2% Bis 1.05 ml 
TEMED 14 µl 
10% APS  210 µl  
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5.6.7. Immunoflurencence  
 
Triton       0.5% Trion in PBSA 
 
PBSA      137 mM Nacl 
      3 mM KCl 
      1.5 mM KH2PO4 
      PH 7.4 
 
Goat serum      10% serum diluted in TBSA 
Donkey serim:     10% serum diluted in TBSA 
 
2% PFA      Paraformaldehyde 4g 
      disstlled water 180 µl 
      10x PBS 20 µl 
      PH 7.4  
 
5.7. Chemical and Kits 
 
Chem Glow Alpha Innotech corporation  CA, USA 
Formaldehyde  Merck 
 Isopropyl alcohol, Sigma (St. Louis, MO) 
 trypsin  Sigma (St. Louis, MO) 
2 (beta )-Mercaptoethanol Sigma (St. Louis, MO) 
ABS (albumin bovine serum ) Sigma (St. Louis, MO) 
Acrylamide Sigma (St. Louis, MO) 
Agarose Sigma (St. Louis, MO) 
Ammoniu Persulfate Sigma (St. Louis, MO) 
Ammoniu Persulfate Sigma (St. Louis, MO) 
Bisacrylamide Sigma (St. Louis, MO) 
BrdU Sigma (St. Louis, MO) 
BSA Sigma (St. Louis, MO) 
Charcoal -stripped FCS C.C.Pro 
chemiluminescence (ECL Sigma (St. Louis, MO) 
Chloroform,  agarose were from Sigma Sigma (St. Louis, MO) 
CPSR1 Sigma (St. Louis, MO) 
Dextrose Sigma (St. Louis, MO) 
DMEM Sigma (St. Louis, MO) 
DNAse  Sigma (St. Louis, MO) 
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DEPC Sigma (St. Louis, MO) 
EDTA Sigma (St. Louis, MO) 
EtBr Sigma (St. Louis, MO) 
Ethanol Merck 
FCS Sigma (St. Louis, MO) 
Formaldehyde, Sigma (St. Louis, MO) 
Formalin Sigma (St. Louis, MO) 
Formamide Merck 
Glacial acetic acid  Sigma (St. Louis, MO) 
Glycine Sigma (St. Louis, MO) 
Guanidine-HCl Sigma (St. Louis, MO) 
H2O DEPC Sigma (St. Louis, MO) 
HEPEA Sigma (St. Louis, MO) 
KCl Sigma (St. Louis, MO) 
KH2PO4 Sigma (St. Louis, MO) 
Lab-Tek chamber slides  Nunc Inc., Naperville, IL, USA 
Methanol Sigma (St. Louis, MO) 
MgSO4.7H2O Sigma (St. Louis, MO) 
MOPS Sigma (St. Louis, MO) 
NuPAGE LDS Sample Buffer Invitrogen, (Carlsbad, CA) 
NuPAGE 4-10% Bis-Tris Gel Invitrogen, (Carlsbad, CA) 
NuPAGE MOPS SDS Running Buffer Invitrogen, (Carlsbad, CA) 
NuPAGE Transfer Buffer Invitrogen, (Carlsbad, CA) 
Na2HPO4 anhydrogenous Sigma (St. Louis, MO) 
Na2HPO47H2O Sigma (St. Louis, MO) 
Na4EDTA  Sigma (St. Louis, MO) 
NaCl Merck 
NaH2PO4 Sigma (St. Louis, MO) 
NaN3 Sigma (St. Louis, MO) 
NaOAc.3H2O Sigma (St. Louis, MO) 
NaOAc.3H2O Sigma (St. Louis, MO) 
Nitrocellulose ECL Membranes Sigma (St. Louis, MO) 
PVDF Membran filter paper invitrogen  
Penicillin Sigma (St. Louis, MO) 
RnaseZAP Ambion Inc. 
PAP pen Daido Sangyo Co., Ltd., Tokyo, Japan 
Plolyvinylidene Fluoride.membranes  Gelman Laboratory 
Sodirmazide Sugma 
Tissue.tec 
Sakura Finetek Europe B.V., Zoeterwoude, The 
Netherlands 
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Tris base Sigma (St. Louis, MO) 
Tween 20 Sigma (St. Louis, MO) 
Vitamin B12 Sigma (St. Louis, MO) 
LPR Kit Supper Array Bioscience Corporation  
Taq PCR Master Mix kit QIAGEN (Hilden ,Germany 
DANfree Kit Ambion Inc.) 
Bio-Rad protein Assay Bio-Rad (munic Germany) 
Protease inhibito cocktail set  Calbiochem (Darmstadt, Germany.) 
Mouse/Rat PDGF-BB ELISA kit R&D systems (Inc. MN ,U.S.A) 
Mouse/Rat TGF-β1 ELISA kit R&D systems (Inc. MN ,U.S.A.) 
Osteonectin ELISA kit  US Biological (Swampscott, USA) 
PCR SuperMix Invitrogen, (Carlsbad, CA) 
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6. Methods  
 
6.1. Animal experiments 
 
6.1.1. Myocardial infarction model in mouse  
 
6.1.1.1. Experimental design      
the experimental protocol for left coronary artery ligation has been previously 
described (Li et al., 1997; Harada et al., 1999) and is routinely performed in our 
laboratory. Mice are sacrificed 2d. 7d, one month and two months after to analyze 
immediate responses Hearts are excised and the infarct size calculated and 
expressed as a percentage of left ventricular surface area. Animals with less than 
30% of infarct size will be excluded from the studies, as they generally do not show 
typical left ventricular remodeling. Ventricles are isolated and snap-frozen in liquid 
nitrogen for gene-expression analyses. Part of the herats is used for 
histopathological analysis.  
 
6.1.1.2. Operational Procedure 
After an adequate depth of anesthesia is attained the mouse is fixed in a supine 
position with tape. A 5-0 ligature is placed behind the front upper incisors and pulled 
taut so that the neck is slightly extended. The tongue is retracted and held with 
forceps, and a 20-G i/v catheter is inserted into the trachea. The catheter is then 
attached to the mouse ventilator via the Y-shaped connector. Ventilation is performed 
with a tidal volume of 200ul and a respiratory rate of 133/min. 100% oxygen is 
provided to the inflow of the ventilator. Prior to the incision the chest is disinfected 
with betadine solution and 70% ethyl alcohol. The chest cavity is opened by an 
incision of the left fourth intercostal space. Chest retractor is applied to facilitate the 
view. The heart is exposed, the pericardial sac is opened and pulled apart, and the 
left anterior descending (LAD) artery is visualized. Ligation is proceeded with a 7-0 
silk suture passed with a tapered needle underneath the LAD artery about 1-2 mm 
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lower than the tip of the left auricle. Occlusion is confirmed by pallor of the anterior 
wall of the left ventricle. A drop of 1% lidocaine is placed on the apex of the of the 
heart to prevent arrhythmia. Lungs are overinflated, and the chest cavity, muscles, 
and skin are closed . 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.1 Induction of myocardial infarction. Myocardial infarction was induced by 
surgical ligation of proximal left anterior descending coronary artery. Sham operated 
animals under went the same procedure except that no ligation was  performed. 
 
 
 
6.1.2. . Pressure overload hypertrophy model in mice-  
 
Chronic pressure-overload LV hypertrophy was induced by aortic banding (AB) in 
wild-type (WT) and integrin beta 1 knock mice. Aortic banding was maintained for two 
days, 7days and one month.  Mice were anesthetized with tribromoethanol / amylene 
hydrate (Avertin; 2.5% wt/vol, 6 µL/g body weight IP). A topical depilatory agent was 
applied to the neck and chest, and the area was cleaned with betadine and alcohol. 
Mice were placed supine, A horizontal skin incision 0.5–1.0 cm in length was made at 
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the level of the suprasternal notch. The thyroid was retracted, and a 2- to 3-mm 
longitudinal cut was made in the proximal portion of the sternum. This allowed 
visualization of the aortic arch under low-power magnification. A wire with a snare on 
the end was passed under the aorta between the origin of the right innominate and 
left common carotid arteries. A 6-0 silk suture was snared with the wire and pulled 
back around the aorta. A bent 27-gauge needle was then placed next to the aortic 
arch, and the suture was snugly tied around the needle and the aorta. After ligation, 
the needle was quickly removed. The skin was closed, and mice were allowed to 
recover on a warming pad until they were fully awake. The sham procedure was 
identical except that the aorta was not ligated.  
 
 
 
 
   
 
Fig. 6.2. Induction of hypertrophy Left ventricular pressure overload hypertrophy in 
these mice was induced by partial banding of the aorta. As a control, a thoracotomy 
was performed on the sham-operated mice without hemodynamic interventions. Under 
this condition, systemic arterial ressure remained unaltered for one week to two 
months. 
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6.1.3. In vivo inhibitior of integrin αv- 
 
Mice were treated in vivo with a specific integrin αv inhibitor 1 day prior to myocardial 
infarction. Alzet osmotic mini pumps were implanted subcutaneously. The release 
rate was 1µl/hour/animal of either a solution of 100 mg/ml of the integrin αv inhibitor in 
50% DMSO/PBS or DMSO/PBS alone (vehicle control). 
 
6.1.4. β1 knock-out mice - 
 
6.1.4.1. Inducible knockouts:  The Cre/lox system 
Adult ß1 conventional knockout mice were obtained from Dr. R. Fässler (Max-Planck-
Institute of Biochemistry, Martinsried, Germany). Cre-knockin mice with a myosin 
light chain 2v driven promotor for cardiac specificity were obtained from Dr. Ken 
Chien (University of San Diego, CA, USA).The myosin light chain 2v (MLC2v) gene is 
expressed bilaterally in the embryo in the cardiac primordial (around  E7.5 in the 
mouse), and is restricted to ventricular precursors and definitive ventricular tissue 
from the linear heart tube stage throughout the entire postnatal time window (O'Brien, 
Lee et al. 1993) Because of the restricted cardiac expression of this gene to the 
ventricles at the earliest stages of ventricular specification, it is chosen to express cre 
recombination under the control of MLC2v regulatory elements. The method for 
conditional gene KO makes use of the site specific recombinase Cre, a 38kDa 
protein from bacteriophage P29. This enzyme can be used to generate tissue-specific 
or inducible knockouts in the genome of mice. Cre is a member of the integrase 
family of recombinases, which can perform an efficient site specific recombination at 
its target site loxP. LoxP sites are 34bp long and contain a 13 bp inverted repeat 
flanking a core region that determines the orientation of the site. The function of Cre 
is to ensure that only monomers of the plasmid are maintained by resolving plasmid 
dimers by site-specific recombination into monomers30. The recombination occurs 
precisely and the loxP sites after recombination are still functional. Thus, the 
recombination is a reversible process. The use of Cre for both site specific mutations 
in ES cells that can be passed into the mouse germline and for conditional KO in vivo 
The most promising aspect of the Cre-loxP System is its application for conditional 
KOs. With the system, it is possible to knock out a gene only in certain cell types or 
tissues. If a gene is needed early in development of the mouse, eliminating it in all 
Methods - 110 - 
 
 
tissues could be lethal, as reported for beta.1-integrin. With a tissue –specific 
knockout this problem can be avoided.  
 
 6.1.4.2. Induction of  heart ventricular integrin β1 knock out in mouse. 
 
1). To engineer the knockout, loxP sites are inserted so they flank the gene of 
interest  and introduced into one mouse strain. 
2). Transgenic mice are also prepared that carry the Cre gene linked to a cell-type 
specific promoter (region on DNA that controls transcription).   
3). Mating of the two strains of mice gives progeny that carry the loxP sites flanking 
the gene of interest and the Cre gene controlled by a cell-type specific promoter.  
Recombination will only occur in the cells where the promoter is active, so the gene 
is only knocked out in certain tissues.   
4.) The mice containing the loxP mutant allele can be crossed with different mouse 
strains with Cre under control of different tissue-specific promoters to look at 
phenotypic effects in different tissues. 
Adult ß1 conventional knockout 
 
6.1.5. Hemodynamic Measurements and Left Ventricular Volume- 
 
Hemodynamic studies were performed either 2days, 7 days and one month after 
coronary artery ligation of MI model or aortic banding mice model according to 
published protocols under light isoflurane anesthesia and spontaneous respiration 
(isoflurane 1.5 vol% supplemented by 0.5 L of oxygen per minute).LV pressure 
curves were recorded after catheter placement in the LV cavity; systolic and diastolic 
blood pressure measurements were obtained on catheter withdrawal in the thoracic 
aorta  All measurements were performed by a single trained investigator blinded to 
genotypes and treatment. Animals with small infarcts (<10% of LV circumference; 
BERKO n=6, WT n=8) and nonphysiological heart rates below 400 bpm (BERKO 
n=2, WT n=3) were excluded from morphometric, hemodynamic, echocardiographic, 
and molecular analyses. r(Hu, Gaudron et al. 1998). 
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6.1.6. Transthoracic Echocardiogram (M-mode) 
 
   
 
 
 
 
 
 
Fig .6.3  Transthoracic Echocardiogram 
(M-mode)The echocardiograph used a 
Toshiba Power Vision 6000 system with a 
15-MHz frequency ultrasound probe under 
general anesthesia with tribromoethanol/amylene hydrate (Avertin; 2.5% wt/vol, 6 µL/g 
body weight IP) under spontaneous respiration at a minimum depth setting of 3 cm  for 
2D (on the right of the figure ) and M-mode imaging.( In the left of the figure, from the 
same mouse in the parasternal short-axis view.)   The 2D images were obtained in white-
on –black format with M-mode imaging and the spectral Doppler tracings in black-on 
white format. 
 
 
6.1.6.1. Echocardiography  
Transthoracic echocardiography is the echocardiogram that is performed by 
positioning a probe, called a transducer, on the outside of the chest wall while the 
mouse is lying down. Sound waves lack the ability to travel through air, so a clear, 
gel-like substance is placed between the chest and the transducer to provide a 
medium through which sound waves can travel. The gel also helps to improve the 
contact between the transducer and the skin. The transducer is placed in various 
positions on the chest to obtain different images of the heart.  
 
6.1.6.2. Measurements. 
Observatons were made in 47 intact, anesthetized mice.  Mice were weighed and 
general anesthesia with tribromoethanol/amylene hydrate under spontaneous before 
the echocardiogram was performed. In later studies, a specially transducer was 
used. With the mouse in the left lateral decubitus position, the transducer was placed 
on the left hemithorax. The correct transducer placement was judged by the round 
appearance of the left ventricular (LV) cavity after angulation and cranio-caudal 
transducer movements. Need to be careful that avoid excessive pressure, which can 
induce bradycardia.  LV end-systolic and end-diastolic areas were calculated by 
manual tracings of the endocardial border followed by planimetry with the Nice 
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software package (Toshiba Medical Systems).and transversal M-mode tracings were 
recorded with the cursor placed in the middle of the LV cavity. Taken the guide of the 
2D parasternal short-axis imaging plane, the LV M-mode tracing was obtained close 
to the papillary muscle level Measurements are taken for anterior and inferior wall-
thickness, left ventricular and end-diastolic dimension..  
 
6.1.7.Ventricular mass calculation 
 
In normal mice and knock out mice with or without transverse aortic constriction after 
echocardiography the experiment was terminated with an overdose of intraperitoneal 
sodium pentobarbital, the heart was excised, the atria and vessels were dissected 
free, and the ventricles are weighed. For normalizing the dates, body weight and the 
tibia are measured as well 
 
 
6.2. RNA isolation  
 
RNA was extracted from mouse heart with different treatments using TRIzol 
(Invitrogen) as described previously (Knepp, Geahr et al. 2003)Total  RNA from 5-6 
each  groups of mice 2d or 1 wk after MI and sham-operated mice Total  RNA from 4 
groups of mice 2d or 1 wk after MI with or without integrin alphv with or without 
integrin alphv. 1ml of TRIZOL was added per tube containing 50-100 mg of heart 
tissue before homogenization. Then, homogenate was mixed well with 0.2 ml of 
chloroform per 1 ml of TRIZOL, and incubated at room temperature for 2-3 min. 
Following centrifugation (12000g for 15 min at 4 ºC), lower phase, interphase and 
upper phase of sample appeared in the tube. The upper phase was removed 
carefully and transferred to a new tube. RNA was precipitated by adding 0.5 ml of 
Isopropanol per 1ml of TRIZOL and incubated at room temperature for 10 min then 
centrifuged at 12000 g for 10 min at 4 ºC. After removing the supernatant, RNA 
pellets were mixed with 75% ethanol and then centrifuged at 7500g × 5 min at 4 ºC. 
After the supernatant was removed, the pellets were permitted to stand for air drying. 
RNA was dissolved in 20 µl of DEPC water and incubated at 55 ºC for 10 min.  
To remove contaminating DNA 0.1 volume of 10X DNase 1 Buffer and 1ul of DNase 
1 were added to the RNA (DNAfree, Ambion Inc.). The RNA solution was mixed 
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gently and incubated at 37ºC for 20-30 min. The DNase Inactivation Reagent was 
resuspended by vortexing the tube and 0.1volume or 5ul was added to RNA solution. 
The tube was incubated for 2 min at room temperature and centrifuged at 10,000x g 
for 1 min to pellet the DNase Inactivation Reagent . The RNA was stored at -80˚C for 
later use. 
 RNA quality was analysed by electrophoresis in formaldehyde containing 1% 
agrose gels using a MOPS buffer. The integrity of the 18 s and 28 s rRNA bands are 
an incication of RNA quality. The concentration is md under UV light by using 
spectrophotometer. Only the ratio at (280nm/ 260 nm) more than 1.8 are considered 
pure RNA and used for further gene array.  
 
  
 
Figure 6.4, RNA electrophoresis Total RNA (5-10 ug) containing ethidium bromide are    
separated electrophoretically using a 1% formaldehyde agarose gel   with a circulating 
running buffer of 1X MOPS for 2 hours .The two bands, upper 28S (5 kb), and the bottom 
18S (2.2 kb), suggested a good quality of RNA. The RNA in the third lane indicated that 
the RNA was degraded. 
 
6.3. cDNA  gene micro Array  
 
6.3.1 RNA preparation and Gene Chip hybridization  
 
 RNA was extracted from mouse hearts with different treatments using TRIzol 
(Invitrogen) as described before. Total RNA from 4 groups of mice 2d or 7d after MI 
with or without integrin alphv was used as starting material and hybridized to the non-
radioactive GEArray TM Q series cDNA array (SuperArray Inc.,USA). This array 
contain 96 sets of biotin deoxyuridine triphosphate (dUTP)-labeled cDNA probes 
(ECM-integrin related gene-specific cDNA fragments).These known genes encoding 
Methods - 114 - 
 
 
cell adhesion and extracellular matrix proteins were specifically generated in the 
presence a designed set of gene-specific primers Intensity differences > 2-fold in 
gene expression are considered significant and selected gene were further analyzed 
through Western blot analysis and immunofluorescence. 
 SouperArray Extracellular matrix Gene Array was using total RNA (5ug per 
membrane) as template for probe synthesis. The dUTP labeled cDNA were 
specifically generated by following protocols of Ampolabeling (LPR kit; Cat#:L-03N) 
The RNA was reverse-transcribed by gene-specific primers with biotin-16-dUTP. 
Biotinylated cDNA probes were denatured and hybridized to the ECM-integrin related 
gene-specific cDNA fragments spotted on the membranes at 60C for 17 h. The 
GEArray membranes were then washed and blocked with GEA blocking solution, 
and incubated with alkaline phosphatase-conjugated streptavidin ( washed twice with 
2x saline sodium citrate buffer (SSC) 1% sodium dodecyl sulfate (SDS) and then 
twice with 0.1 x SSC/1% SDS at 60 C for 15 min each.) Chemiluminescent detection 
steps were performed by subsequent incubation of the membranes with alkaline 
phosphatase-conjugated streptavidin and CDP-Star substrate. The results were 
analyzed using ScanAlyze 2 software. All cDNA microrray experiments were 
performed twice with new filters. The positive and negative spots were identified and 
matched by at least two experiments are presented. Each array membrane 
comprised 96 marker gees, four positive controls including beta-actin, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), cyclophilin A, and ribosomal 
protein L13a; and a negative control, bacterial plasmid pUC18. The relative 
expression levels of different genes were estimated by comparing its signal intensity 
with that of internal control GAPDH.  
 
6.3.2 Post-Hybridization Data Analysis  
 
The gene expression profile could easily distinguish during 4 different independence 
experiments. To quantify the results, we normalize the intensity data by first 
subtracting the average background (mean blank intensity) and then comparing 
intensity levels with the average intensity of the hybridization signal of the house 
keeping gene. 
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Figure 6.5. Process of cDNA gene array was shown as indicated.(from SuperArray Inc.,USA)  
 
6.4. Cell isolation and cell culture  
 
6.4.1.Isolation of rat neonatal cardiomyocytes 
 
Cardiac myocytes were isolated and cultured from neonatal rat hearts based on the 
method reported previously (Tamamori-Adachi, Hayashida et al. 2004; Burkard, 
Becher et al. 2005). Experiments were performed according to Institutional Animal 
Care and Use Committee and NIH guide lines. Hearts were removed from 1- to 2-
day-old neonatal wistar rats after decapitation and kept in CBFHH (137 mM NaCl, 
5.36 mM KCl, 0.1 mM  MgSO4 H2O, 5.5 mM  Dextrose, 0.44 mM KH2PO4, 0.4 
Na2HPO4, Hepes, pH 7.4) with 0.3% Heparin. Ventricles were trimmed free and 
minced with dissecting scissors (minced ventricles). Cells were washed one time by 
T&D (1ml Dnase per 100ml trypsin) and then dissociated at room temperature using 
a magnetic stir bar at the lowest speed (100-150rpm) with 15 ml T&D 15 min at 37 
oC. Transfer supernatant to 3.75% FBS, observe a drop of the supernatant under 
microscope every time till there no more cardiomyocytes left. Cells were pelleted by 
centrifugation at 1600 r.p.m for 5 minutes at room temperature. The supernatant was 
Methods - 116 - 
 
 
discarded and cells were resuspended in complete medium [ MEM  ( Minimum 
Essential Medium from Sigma), plus 0,1mM BRdU, penicillin G streptomycin 0,01% 
vintaminB (Sigma)] with 5%FBS (Sigma), then filtered through a metal sieve to filter 
out large material. The resulting mixture was pre-plated for 1.5h in 37 °C, 0.1% CO2 
incubator. Cells still in suspension were enriched with myocytes and were plated on 
6-well dishes at high density (600,000 cells each well and 200,000 cells each 
chamber slide) and maintained in MEM with 5 % fetal bovine serum for 24 hours. 
Following 12 h serum starvation (0.5% FBS) cells were treated by adding TGF-β1 
(10ng/ml) or PDGF-BB (10ng/ml) for 72 h. The Condition medium was assessed the 
expression of SPARC by Western blotting. When the expression was assessed 
immunohistochemically, the isolated cells were cultured under the same conditions 
on Lab-Tek chamber slides (Nunc Inc., Naperville, IL, USA). Non-myocyte 
contamination of primary cultures 46h after isolation consisted of approximately 5% 
of the total cell population. Myocardial cells were morphologically distinguished by a 
coarse, granular cytoplasm containing small, dense nuclei, whereas non-myocytes 
were readily distinguished by a phase-lucent cytoplasm. 
 
6.4.2. Cell culture of fibroblasts 
 
 Mouse fibroblasts were maintained on cell culture dishes in DMEM supplemented 
with 10% fetal bovine serum (FBS), non-essential amino acids for MEM, penicillin 
(50U/ml), streptomycin (50µl/mi) at 370C, 5% CO2. Cells were grown to confluence 
and passaged with 0.25% trypsin and 0.02 % EDTA in sterile PBS, for 2 min. 
Detached cells were mixed with serum and centrifuged for 3 min at 600 rpm. Cells 
were employed in the experiments of migration assay at between fourth and sixth 
passage. 
 
 
6.5. DNA Isolation from mice tail. 
 
DNA from mouse tails was isolated according to the protocol of the manufacturer 
(QIAGEN). 0.4-0.6 cm of mouse tail was cut into a 1.5-ml microcentrifuge tube. 180 
µl Buffer ATL was added to the tube. The tail tissue was digested by 40 µl of 
proteinase K at 55˚C. The tube was vortexed occasionally during digestion. Lysis 
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was usually complete in 6-8h. 4ul of RNase A (100mg/ml) was added to the sample, 
mixed by vortexing, and incubated for 2min at room temperature. After vortexing for 
15sec, 400 µl Buffer AL-ethanol was added to the sample and mixed vigorously by 
vortexing. The mixture was then pipetted into the mini column sitting in a new 2-ml 
collection tube and centrifuged at 6000 g for 1 min. Flow through was discarded. The 
mini column was placed in a new 2-ml collection tube and 500 ul of Buffer AW1 was 
added to the column. After centrifugation (6000 g x 1min), flow through was 
discarded. The mini column was placed in a new 2-ml collection tube and 500 µl of 
Buffer AW2 was added to the column. After centrifugation (6000 g x 1min), flow 
through was discarded. The column was re- centrifuged for 1 min at full speed.  The 
mini column was placed in a clean 1.5 ml or 2-ml microcentrifuge tube and 200 µl 
Buffer AE was directly pipetted onto the membrane. The column was incubated at 
room temperature for 1 min, and then centrifuged for 1 min at 6000 g to elute the 
DNA.  
 
 
6.6. PCR 
 
A Cre5’ primer (5’-AAC ATG CTT CAT CGT CGG), a Cre3’ primer (5’-TTC GGA TCA 
TCA GCT ACA CC-3’), a primer L26 (5’-TAA AAA GAC AGA ATA AAA CGC AC-3’) a 
primer T56 (5’-AGG TGC CCT TCC CTC TAG A-3’)and a primer L1(5’-GTG AAG 
TAG GTG AAA GGT AAC-3 ‘) were used for genotyping of the KO mice. The Taq 
PCR Master Mix (+ Q-solution) from Qiagen was mixed on ice with template DNA 
(0.5 to 1.0 µg /reaction) and specific primers (0.25 µl/reaction from 100 µM stock final 
conc. 0.4 µM). The final volume of the PCR reaction was 50 µl. For beta.1 
heterozygous KO (beta.1 +/-) the primer combination L26 and T56 was used to 
detect the neomycin cassette in the KO allele, which yielded in a 210 bp product. For 
beta.1 conditional KO (beta.1 c/c) the primers T56 and L1 were used and showed a 
400 bp product for homozygous conditional KO (beta.1 c/c), a 320 bp product for WT 
(beta.1 +/+) or both products for heterozygous conditional KO (beta.1 c/+). For 
detection of mice heterozygous for Cre-recombinase (Cre +/-) the primers Cre 5’ and 
Cre 3’ were used and yielded in a 419 bp product. The thermal cycler was 
programmed for 1 cycle 4 min at 94˚C followed by 20 cycles of 0.5 min at 94 ˚C, 1 
min at 63 ˚C with touchdown (0.5°/cycle) to 53°C, 1 min at 72 ˚C, followed by 20 
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cycles of 0.5 min at 94 ˚C, 1 min at 53°C, 1 min at 72 ˚C and a final extension of 4 
min at 72°C. The PCR product was confirmed by agarose gel electrophoresis. 
 
 
6.7. Protein methods  
 
6.7.1. Protein extraction for Western blotting  
 
Proteins are extracted from tissue or cultured cells by lysis of cells in RIPA buffer or 
homogenisation of tissue in 2% Tris-Triton Lysis Buffer. Detergent soluble fractions 
were prepared from the supernatant, after 14000 g centrifugation for 10 min at 4°C to 
remove nuclei and the insoluble fraction then stored at- 80o C. Protein concentration 
was determined by the Bradford protein assay using a BSA standard curve. 
 
6.7.2. Preparation of Conditional medium for Western blotting 
 
Proteins in CM were precipitated by adding 3 volumes of precooled ethanol for each 
volume of CM and the mixture was stored at -20oC for 20 h. Proteins were separated 
by centrifuging at 4 oC and 15.000g 30 min. The dry precipitate was dissolved in 
phosphate- buffered saline. Protein concentration was determined with a Bio-Rad 
protein assay kit using BSA as standard. 
 
6.7.3. Western blotting  
 
 By adding an aliquot of Laemmli SDS sample buffer followed by 5 min boiling at 
95°C, 15 µl of the samples from the heart tissue were separated on 7.5% -15% SDS 
polyacrylamide gels depending on the size or target protein and electrophoretically 
transferred to nitrocellulose membranes Plolyvinylidene Fluoride.membranes 
(Gelman Laboratory). Then, the proteins were transferred to Plolyvinylidene Fluoride 
membranes (Gelman Laboratory). After transfer, the membranes were blocked for 1 
hour using 10% non-fat milk or 3% ABS) in TBST Buffer. Blots are incubated with the 
primary antibody in TBST buffer overnight at 4˚C with light agitation. After incubation 
with primary antibody, the membranes are washed 5 times with large volumes of 
TBST and incubated with a horseradish peroxidase labelled secondary antibody in 
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TBST buffer for 1 hour at room temperature, the blots were detected by enhanced 
chemiluminescence (ECL) accordining to the manufacturer’s reonmmendations. The 
signal was detected by a digital imaging system (ALPHA Innotech ChemiImager 
5500).  
 
6.7.4. ELISA 
 
ELISA assay. The TGF-β1 protein and PDGF-BB protein were quantitated using the  
Quantikine mouse TGF-β1 kit and PDGF-BB kit  respectively ( R&D System, 
Minneapolis, MN). SPARC protein was quantitated using Osteonectin (SPARC) 
ELISA kit (US Biological, Swampscott, USA). Cells were processed and assayed 
according to the manufacturer’s protocol (xx). Briefly, serum starved fibroblasts were 
treated with vitronectin (VN1µg/ml) 48 hours or PBS with or without 10mM integrin αv 
inhibotor. For SPARC induction, cells were treated by TGFβ1(5ng/ml) or PDGF-
BB(5ng/ml) After treatment, conditioned medium was collected by centrifugation at 
600x g for 5 min and stored at -800 C until the assay was performed. The TGF and 
PDGF protein concentration in the conditioned medium was determined by plotting 
absorbance at dual wavelength of 570 for know on a standard curve derived from 
dilutions of TGF and PDGF standard. SPARC was determined by plotting 
absorbance at dual wavelength of 490 for know on a standard curve derived from 
dilutions of SPARC standard. Each treatment was performed in triplicate. Cell 
numbers were determined and protein values were normalized to cell number. 
 
6.8. Immunofluorescence  
 
6.8.1. Immunofluorescence for frozen mouse heart tissue  
 
Fresh frozen mice ventricular tissue sections (5 µm) from mouse hearts were 
mounted on slides Then fixed in 4% paraformaldehyde 15 minutes and 1% Triton X-
100 prepared in TBS 20 minutes. After blocking the sections with 10% goat serum in 
TBS containing 1% bovine serum albumin (TBSA), they were incubated with primary 
antibodies goat polyclonal IgG anti-SPARC antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) at a dilution of 1:100 overnight. The sections were further 
incubated with fluorescence-labeled secondary antibodies anti-goat 488 (Cy-2-
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conjungated), as well as Phalloidin (alex 546) at a dilution of 1:40 and Dapi at a 
dilution of 1:500.  Between steps, sections were washed three times for 5 min with 
TBS. All dilutions were performed with TBSA. Negative controls wee processed using 
anti-SPARC exposed blocking peptide at a dilution of 1: 10 one hour, or using TBS 
alone (without antibody, etc.) in some other incubation step 
 
6.8.2. Duplicate immunofluorescence for isolated cardiomyocytes 
 
Isolated neonatal rats cardiomyocytes were fixed in by immersion for 15 min in 4% 
paraformaldehyde and 20 min in 1% Triton X-100 prepared in PBS, washed three 
times by PBS. Goat polyclonal IgG anti-SPARC antibody Anti-SPARC was used at a 
dilution of 1:100 as the first antibody. Isolated Rats cells from heart were identified as 
cardiomyocytes by staining with a 1:250 dilution of  a rabbit polyclonal antibody  
raised against a recombinant protein corresponding to amino acids of cardiac muscle 
Troponin I of human origin. (Anti-Troponin I antibody, from Santa Cruz) After 
overnight incubation, the sections were further incubated with fluorescence-labeled 
secondary antibodies anti-goat 580 (Cy-2-conjungated) and anti-rabbit 488 (Cy-3-
conjungated) at a dilution of 1: 250 for one hour. Then staining the neucleur by Dapi 
at a dilution of 1:500 Between steps, sections were washed three times for 5 min with 
PBS. Negative controls wee processed using anti-SPARC exposed blocking peptide 
at a dilution of 1: 10 one hour, or using PBS alone (without antibody, etc.) in some 
other incubation step.Microscopy: Sections were observed and photographed using a 
microscope (Olympus, Tokyo, Japan)   
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6.9. Migration Assay 
 
 
 
Figure. 6.6. Schematic drawing of haptotaxis cell migration. Cell Migration Assay Kit 
contains polycarbonate membrane (8µl pore size) in a 24 –well palte. The membrane serves 
as a barrier to discriminate and ultimately pass through the pores of the polycarbonate 
membrane. After 6-18 hours, the cells from the top of the membrane are removed and the 
migratory cells are stained and quantified.   
 
 
Millicell modified Boyden chambers (8 µm pore size; Millipore, Bedford, MA) were 
employed in haptotaxis assays as previously described (Hauck, Hsia et al. 2002). 
Briefly, the lower surface of the Millicell polycarbonate membrane was coated with 
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100 µl of the indicated proteins or 0.5% BSA in DMEM for 2 hours at room 
temperature. After washing the chambers with PBS and air-drying, 1x105 serum-
starved cells were added in 0.3 ml migration medium (DMEM with 0.5% BSA). 
Cambers were placed into 24-well plates containing 0.4 ml migration medium. After 7 
hours at 37°C, the cells on the upper surface of the membrane were removed by a 
cotton tip. The migratory cells on the lower membrane surface were fixed by 
methanol/acid treatment and stained with crystal violet (0.1% crystal violet, 0.1 M 
borate pH 9.0, 2% ethanol). Haptotaxis was quantified by counting cells in 5 random 
fields/chamber using a 20x objective in three individual chambers per sample or/ and 
by measuring absorbance at 600 nM. Each determination represents the average of 
three individual wells and error bars represent standard deviation (s.d). By cell 
counting methods background levels of cell migration to 0.5% BSA were <1%of 
values obtained with FN. Data presented are representative of at least three separate 
experiments.   
 
6.10. Software and websites 
 
z Microsoft Office , 
z EndNote program 
z Microsoft Access 
z Adobe photoshop 
z Adobe reader  
z ScanAlyze 2  
z Sigma  
z Startview  
z CoreIDRAW 
 
WebPrimer-http://genome-www2.stanford.edu/cgi-bin/SGD/web-primer 
The Web Primer provides tools for the purpose to design primers. Current choices 
are limited to sequencing and PCR alignment  
NCBI Nucleotide- ttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi   
The Entrez Nucleotides database is a collection of sequences from several sources, 
including GenBank. 
NCBI BLAST-http://www.ncbi.nlm.nih.gov/BLAST/ 
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 (Basic Local Alignment Search Tool) is a set of similarity search programs designed 
to explore all of the available sequence databases regardless of whether the query is 
protein or DNA. The program compares nucleotide or protein sequences to sequence 
databases and calculates the statistical significance of matches. BLAST can be used 
to infer functional and evolutionary relationships between sequences as well as help 
identify members of gene families.  
 
6.11. Lab devices  
 
z ChemiImagerTM 5500 from ALPHA Innotech. ( San Leandro, CA). 
z Mastercycler PCR System from eppendof (Hamburg, Germany) 
z Ultrospec 3000 spectrophotometer from Pharmacia Biotech AB (Cambridge, 
England) 
z Microscopes    
z UV lamp from Bio RAD  
z Incubators 
z Vacuum dryer  
z Autoclaves  
z Centrifuges 
z  Heating blocks  
z Water bath  
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Abbreviations  
A260 absorbance at 260 nm 
aa amino acids 
Ag antigen 
ANP atrial natriuretic peptide 
ATG Base triplet coding for methionine; translational start site  
BNP brain natriuretic peptide 
BSA bovine serum albumin  
BW body weignt  
cDNA complementary DNA 
CF cardiac failure  
Cre Cre (causes recombination) recombinase 
DMEM Dulbecco’s minimum essential medium 
DMSO dimethylsulfoxid  
DNA desoxyribonucleic acid 
dp/dt max velocity of systolic LV pressure development  
dp/dt min velocity of diastolic LV relaxation   
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid  
EGF epidermal growth factor 
Erk Extracellular signal-regulated kinase  
FAK focal adhesion kinase 
FCS fetal calf serum 
FGF fibroblast growth factor 
FN fibronectin  
FS fractional shortening  
HW heart weight  
IGF Insulin-like growth fachor 
IVS inventricular septum  
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Jnk c-jun N-terminal kinase 
Kb kilobases  
kDa kilodalton 
loxP recognition site for Cre recombinase 
LV   left ventricle  
LVEDP LV end diastolic pressure  
MAPK mitogen-activated protein kinase 
MHC major histocompatibility complex 
MI myocardial infarction  
mRNA messenger RNA 
OD optical density 
PBS phosphate-buffered saline  
PCR polymerase chain reaction  
PDGF platelet derived growth factor 
PFA paraformaldehyd  
RGD arginine glycine aspartate  
RNA ribonucleic acid  
Rnase ribonuclease 
rpm rotations per minute  
RT-PCR reverse-transcriptase polymerase chain reaction 
SDS sodium dodecyl sulphate  
SPARC  secreted protein, acidic and rich in cystein 
c-Src c-Src-kinase 
TGF transforming growth factor 
VN vitronectin  
WT wildtype  
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